

Financial news for SGEN dated on 2020-06-10: Cramer Shares His Thoughts On Marriott, Tegna And More

Financial news for SGEN dated on 2020-06-01: Oppenheimer Maintains Outperform on Seattle Genetics, Raises Price Target to \$175

Financial news for SGEN dated on 2020-05-29: Seattle Genetics Reports Results From Exploratory Analyses Of HER2CLIMB For TUKYSA In Brain Metastases Patients With HER2-Positive Breast Cancer

Financial news for SGEN dated on 2020-05-26: Benzinga's Top Upgrades, Downgrades For May 26, 2020

Financial news for SGEN dated on 2020-05-26: Seattle Genetics shares are trading higher after JMP Securities initiated coverage on the stock with a Market Outperform rating and a \$185 price target.

Financial news for SGEN dated on 2020-05-26: JMP Securities Initiates Coverage On Seattle Genetics with Market Outperform Rating, Announces Price Target of \$185

Financial news for SGEN dated on 2020-05-14: Seattle Genetics Reports ADCETRIS Receives European Commission Approval For Treatment Of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma

Financial news for SGEN dated on 2020-05-12: Seattle Genetics Reports TUKYSA Approval For Treatment Of Patients With Metastatic HER2-Positive Breast Cancer In Switzerland

Financial news for SGEN dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for SGEN dated on 2020-05-05: Shares of several healthcare companies are trading higher amid positive investor sentiment as some US states begin to reopen their economies and as oil prices gain for the session.

Financial news for SGEN dated on 2020-05-05: Stocks That Hit 52-Week Highs On Tuesday

Financial news for SGEN dated on 2020-05-04: Morgan Stanley Maintains Equal-Weight on Seattle Genetics, Raises Price Target to \$149

Financial news for SGEN dated on 2020-05-01: CFRA Maintains Sell on Seattle Genetics, Raises Price Target to \$129

Financial news for SGEN dated on 2020-05-01: Seattle Genetics shares are trading higher after the company reported better-than-expected Q1 sales. Guggenheim upgraded the stock from Neutral to Buy.

Financial news for SGEN dated on 2020-05-01: Morning Market Stats in 5 Minutes

Financial news for SGEN dated on 2020-05-01: Stocks That Hit 52-Week Highs On Friday

Financial news for SGEN dated on 2020-05-01: Benzinga's Top Upgrades, Downgrades For May 1, 2020

Financial news for SGEN dated on 2020-05-01: RBC Capital Maintains Outperform on Seattle Genetics, Raises Price Target to \$149

Financial news for SGEN dated on 2020-05-01: Stifel Maintains Hold on Seattle Genetics, Raises Price Target to \$127

Financial news for SGEN dated on 2020-05-01: HC Wainwright & Co. Maintains Buy on Seattle Genetics, Raises Price Target to \$175

Financial news for SGEN dated on 2020-05-01: Needham Maintains Buy on Seattle Genetics, Raises Price Target to \$163

Financial news for SGEN dated on 2020-05-01: SVB Leerink Maintains Outperform on Seattle Genetics, Raises Price Target to \$155

Financial news for SGEN dated on 2020-05-01: Guggenheim Upgrades Seattle Genetics to Buy

Financial news for SGEN dated on 2020-04-30: CORRECTION: Seattle Genetics Q1 Total Sales \$234.5M, Beats Estimate

Financial news for SGEN dated on 2020-04-30: Seattle Genetics Q1 EPS \$(0.980) Misses \$(0.790) Estimate, Sales \$198.500M Miss \$207.140M Estimate

Financial news for SGEN dated on 2020-04-30: The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1

Financial news for SGEN dated on 2020-04-28: The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update

Financial news for SGEN dated on 2020-04-27: Stocks That Hit 52-Week Highs On Monday

Financial news for SGEN dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for SGEN dated on 2020-04-24: The Daily Biotech Pulse: FDA Approves Sanofi's Meningococcal Vaccine, Pluristem Secures \$54M In Funding For COVID-19 Treatment, Oric Pharma Prices IPO

Financial news for SGEN dated on 2020-04-21: The Daily Biotech Pulse: Applied DNA Begins Validating COVID-19 Test, Cara's Positive Readout, Novan Explores Strategic Alternatives

Financial news for SGEN dated on 2020-04-20: BMO Capital Reiterates Outperform on Seattle Genetics, Raises Price Target to \$154

Financial news for SGEN dated on 2020-04-20: SVB Leerink Maintains Outperform on Seattle Genetics, Raises Price Target to \$146

Financial news for SGEN dated on 2020-04-20: Stocks That Hit 52-Week Highs On Monday

Financial news for SGEN dated on 2020-04-20: Stifel Maintains Hold on Seattle Genetics, Raises Price Target to \$120

Financial news for SGEN dated on 2020-04-20: Oppenheimer Maintains Outperform on Seattle Genetics, Raises Price Target to \$146

Financial news for SGEN dated on 2020-04-20: RBC Capital Maintains Outperform on Seattle Genetics, Raises Price Target to \$147

Financial news for SGEN dated on 2020-04-20: 10 Biggest Price Target Changes For Monday

Financial news for SGEN dated on 2020-04-20: Shares of Seattle Genetics are trading higher after analysts at Needham reiterated a buy rating on the stock and raised their price target to \$157.

Financial news for SGEN dated on 2020-04-20: Needham Maintains Buy on Seattle Genetics, Raises Price Target to \$157

Financial news for SGEN dated on 2020-04-17: Seattle Genetics Press Release Confirms Earlier Report From FDA Of Approval For TUKYSA For Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

Financial news for SGEN dated on 2020-04-17: Seattle Genetics Shares Sell Off From Session High, Down ~1.5% From Session High

Financial news for SGEN dated on 2020-04-17: UPDATE: FDA Says, As Part Of Project Orbis, Granted Approval Of Seattle Genetics' Tukysa Breast Cancer Treatment

Financial news for SGEN dated on 2020-04-17: Seattle Genetics Shares Spike To Session High, Up 0.8%, Amid Report FDA Approved First New Drug Under Int'l. Collaboration, A Treatment For Patients With HER2-Positive Metastatic Breast Cancer

Financial news for SGEN dated on 2020-04-17: FDA Approves Tukysa, Tucatinib

Financial news for SGEN dated on 2020-04-17: Stocks That Hit 52-Week Highs On Friday

Financial news for SGEN dated on 2020-04-17: The Daily Biotech Pulse: Moderna Secures \$483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement

Financial news for SGEN dated on 2020-04-16: Shares of several healthcare companies are trading higher. Strength could potentially be related to the increased demand in medical products stemming from the coronavirus pandemic.

Financial news for SGEN dated on 2020-04-16: Stocks That Hit 52-Week Highs On Thursday

Financial news for SGEN dated on 2020-04-15: Morgan Stanley Maintains Equal-Weight on Seattle Genetics, Raises Price Target to \$111

Financial news for SGEN dated on 2020-04-14: Shares of several healthcare companies are trading higher as markets gain on positive coronavirus outlook. Other potential positive sector catalysts include demand for therapies and medical supplies amid the

coronavirus pandemic.

Financial news for SGEN dated on 2020-04-08: The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO

Financial news for SGEN dated on 2020-04-07: The Daily Biotech Pulse: Sanofi, Regeneron Finalize Praluent Restructuring, Natus Pre-Announces Q1 Shortfall, Alcon To Delay Dividend Initiation

Financial news for SGEN dated on 2020-04-06: Shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several US hotspots may be peaking. A sooner peak could mean a sooner return to economic activity.

Financial news for SGEN dated on 2020-04-02: Seattle Genetics Announces Potential Accelerated Approval Pathway In The US For Padcev In Combination With Immune Therapy Pembrolizumab As First-line Treatment For Advanced Urothelial Cancer

Financial news for SGEN dated on 2020-03-27: Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.

Financial news for SGEN dated on 2020-03-13: Shares of several healthcare companies are trading higher as the market rebounds following Thursday's selloff. NOTE: Since the coronavirus outbreak the healthcare sector has been extremely volatile.

Financial news for SGEN dated on 2020-03-04: Shares of several healthcare-related companies are trading higher after Joe Biden secured several key wins in Super Tuesday. Biden's more 'moderate' healthcare policies have been seen as more favorable for the sector.

Financial news for SGEN dated on 2020-03-02: Seattle Genetics shares are trading lower. Traders attribute weakness to positive trial results from competitor Merck's KEYNOTE-204 trial of Keytruda.

Financial news for SGEN dated on 2020-03-02: Seattle Genetics Cancels Out of Cowen Healthcare Conference, Blames Coronavirus

Financial news for SGEN dated on 2020-02-26: Seattle Genetics shares are trading higher potentially on a rebound with the overall market after it traded lower on Tuesday amid coronavirus fears.

Financial news for SGEN dated on 2020-02-19: Seattle Genetics And Astellas Received FDA Breakthrough Therapy Designation For Its PADCEV In Combination With Pembrolizumab In First-Line Advanced Bladder Cancer

Financial news for SGEN dated on 2020-02-18: Benzinga's Top Upgrades, Downgrades For February 18, 2020

Financial news for SGEN dated on 2020-02-18: A Peek Into The Markets: US Stock Futures Drop After Apple Warning

Financial news for SGEN dated on 2020-02-18: Barclays Downgrades Seattle Genetics to Equal-Weight, Announces \$124 Price Target

Financial news for SGEN dated on 2020-02-13: Seattle Genetics Reports FDA Filing Acceptance For Priority Review Of Tucatinib New Drug Application

Financial news for SGEN dated on 2020-02-12: The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Financial news for SGEN dated on 2020-02-12: H.C. Wainwright Reiterates Buy on Seattle Genetics, Raises Price Target to \$150

Financial news for SGEN dated on 2020-02-11: Seattle Genetics shares are trading higher after the company announced an update to its Phase 1b/2 trial of PADCEV. Goldman Sachs also maintained a Buy rating on the stock and increased its price target from \$126 to \$165 per share.

Financial news for SGEN dated on 2020-02-11: Stocks That Hit 52-Week Highs On Tuesday

Financial news for SGEN dated on 2020-02-11: Goldman Sachs Maintains Buy on Seattle Genetics, Raises Price Target to \$165

Financial news for SGEN dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for SGEN dated on 2020-02-10: Seattle Genetics And Astellas Announce Updated Results From Phase 1b/2 Trial Of PADCEV; After Median Follow-Up, 73% Of Patients Had Confirmed Tumor Response With Majority Of Responses Still Ongoing, No New Safety Signals Observed

Financial news for SGEN dated on 2020-02-10: Seattle Genetics shares are trading lower potentially on profit-taking after the stock rallied roughly 6% following Q4 earnings.

Financial news for SGEN dated on 2020-02-07: Seattle Genetics shares are trading lower following Q4 earnings results. The company's Adcetris sales came in below consensus estimates while 2020 guidance was also soft.

Financial news for SGEN dated on 2020-02-06: Seattle Genetics shares are trading lower after the company reported Q4 earnings results.

Financial news for SGEN dated on 2020-02-06: Seattle Genetics Q4 Adj. EPS \$(0.14) Up From \$(0.75) YoY, Sales \$289.8M Beat \$224.5M Estimate

Financial news for SGEN dated on 2020-02-06: The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs

Financial news for SGEN dated on 2020-02-05: Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.

Financial news for SGEN dated on 2020-02-02: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Financial news for SGEN dated on 2020-01-31: Seattle Genetics Reports EMA Validation For Co.'s Marketing Authorization Application For Tucatinib For Patients With Locally Advanced or Metastatic HER2-Positive Breast Cancer

Financial news for SGEN dated on 2020-01-28: Benzinga's Top Upgrades, Downgrades For January 28, 2020

Financial news for SGEN dated on 2020-01-28: BMO Capital Initiates Coverage On Seattle Genetics with Outperform Rating, Announces \$139 Price Target

Financial news for SGEN dated on 2020-01-27: Seattle Genetics shares are trading lower in sympathy with the overall market as the Wuhan coronavirus continues to spread throughout the country, prompting travel bans in multiple Chinese cities. Reports say the death toll rose to 80 people.

Financial news for SGEN dated on 2020-01-21: Seattle Genetics Achieves Milestone Following European Commission Approval Of Roche's Polivy

Financial news for SGEN dated on 2020-01-17: Morgan Stanley Maintains Equal-Weight on Seattle Genetics, Lowers Price Target to \$115

Financial news for SGEN dated on 2020-01-14: Seattle Genetics shares are trading higher. Not seeing any company-specific news to justify the price action.

Financial news for SGEN dated on 2020-01-02: Guggenheim Securities Downgrades Seattle Genetics to Neutral

Financial news for SGEN dated on 2019-12-23: Seattle Genetics Announces Submission Of Tucatinib New Drug Application To FDA For Patients With Locally Advanced Or Metastatic HER2-Positive Breast Cancer

Financial news for SGEN dated on 2019-12-22: The Week Ahead In Biotech: Correvio, Intra-Cellular Therapies Await FDA Decisions

Financial news for SGEN dated on 2019-12-19: Seattle Genetics Drug For Difficult-To-Treat Urothelial Cancer Gets Early FDA Nod

Financial news for SGEN dated on 2019-12-19: 36 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for SGEN dated on 2019-12-19: Seattle Genetics shares are trading higher after the FDA granted accelerated approval to its PADCEV for the treatment of adult patients with locally advanced or metastatic urothelial cancer.

Financial news for SGEN dated on 2019-12-19: 28 Stocks Moving in Thursday's Pre-Market Session

Financial news for SGEN dated on 2019-12-19: The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic

Financial news for SGEN dated on 2019-12-19: FDA Grants Accelerated Approval to Astellas' and Seattle Genetics' PADCEV for People with Locally Advanced or Metastatic Urothelial Cancer

Financial news for SGEN dated on 2019-12-18: Seattle Genetics Announces US FDA Grants Breakthrough Therapy Designation For Tucatinib In Locally Advanced Or Metastatic HER2-Positive Breast Cancer

Financial news for SGEN dated on 2019-12-16: Shares of healthcare companies are trading higher on reports suggesting Congress will permanently repeal three major Obamacare-related health industry taxes as part of fiscal 2020 spending bills.

Financial news for SGEN dated on 2019-12-12: Oppenheimer Maintains Outperform on Seattle Genetics, Raises Price Target to \$124

Financial news for SGEN dated on 2019-12-11: 'SGEN Tucatinib pivotal HER2CLIMB data out at #SABC19 Beautiful PFS and OS curves and great news for MBC patients! #BCSM PFS HR=0.54 OS HR=0.66 Another amazing drug out of \$ARRY's powerful discovery machine!' -Tweet From Andy Biotech

Financial news for SGEN dated on 2019-12-11: Seattle Genetics Highlights Presentation Of Tucatinib HER2CLIMB Trial Results

Financial news for SGEN dated on 2019-12-11: The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint

Financial news for SGEN dated on 2019-12-10: UPDATE: Morgan Stanley Initiates Seattle Genetics With Equal-Weight, \$123 Target Notes '2019 has been a pivotal year with upside data on the pipeline beyond lead asset Adcetris'; Equal-Weight, \$123 Target Reflects 'current high expectations'

Financial news for SGEN dated on 2019-12-10: Benzinga's Top Upgrades, Downgrades For December 10, 2019

Financial news for SGEN dated on 2019-12-10: Morgan Stanley Initiates Coverage On Seattle Genetics with Equal-Weight Rating, Announces \$123 Price Target

Financial news for SGEN dated on 2019-12-09: Seattle Genetics, Takeda Report Added Analyses Of ADCETRIS ECHELON-1, ECHELON-2 Phase 3 Trials At ASH

Financial news for SGEN dated on 2019-12-07: Seattle Genetics Announces Updated Data of ADCETRIS in Combination with OPDIVO in Frontline and Relapsed or Refractory Hodgkin Lymphoma at ASH ASH 2019

Financial news for SGEN dated on 2019-12-07: The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling

Financial news for SGEN dated on 2019-12-02: Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.

Financial news for SGEN dated on 2019-12-02: Seattle Genetics Announces Collaboration with Merck to Evaluate its Enfortumab in Combination with KEYTRUDA

Financial news for SGEN dated on 2019-11-26: The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

Financial news for SGEN dated on 2019-11-25: Seattle Genetics Reports Health Canada Approval Of ADCETRIS In Combo With Chemotherapy In Frontline CD30-Expressing Peripheral T-Cell Lymphoma

Financial news for SGEN dated on 2019-11-22: AstraZeneca CEO: Closing In On A Cancer Cure

Financial news for SGEN dated on 2019-11-21: The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon

Financial news for SGEN dated on 2019-11-20: Stocks That Hit 52-Week Highs On Wednesday

Financial news for SGEN dated on 2019-11-20: The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data

Financial news for SGEN dated on 2019-11-19: The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout

Financial news for SGEN dated on 2019-11-18: Stocks That Hit 52-Week Highs On Monday

Financial news for SGEN dated on 2019-11-15: Stocks That Hit 52-Week Highs On Friday

Financial news for SGEN dated on 2019-11-15: The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval

Financial news for SGEN dated on 2019-11-14: Stocks That Hit 52-Week Highs On Thursday

Financial news for SGEN dated on 2019-11-14: The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing

Financial news for SGEN dated on 2019-11-13: The Daily Biotech Pulse: Merck Goes Shopping, Nuvecra Files For Bankruptcy Protection, Opiant Rips Higher

Financial news for SGEN dated on 2019-11-12: Seattle Genetics Submits Arbitration Demand Against Daiichi Sankyo Over Technology Ownership

Financial news for SGEN dated on 2019-11-12: Stocks That Hit 52-Week Highs On Tuesday

Financial news for SGEN dated on 2019-11-05: The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment

Financial news for SGEN dated on 2019-11-05: Seattle Genetics Responds to Daiichi Sankyo's Complaint for Declaratory Judgment

Financial news for SGEN dated on 2019-10-29: Seattle Genetics Narrows FY19 ADCETRIS Net Sales Guidance From \$610M-\$640M To \$625M-\$640M

Financial news for SGEN dated on 2019-10-29: Seattle Genetics Q3 EPS \$(0.55) Misses \$(0.35) Estimate, Sales \$213.3M Beat \$211.83M Estimate

Financial news for SGEN dated on 2019-10-29: Stocks That Hit 52-Week Highs On Tuesday

Financial news for SGEN dated on 2019-10-29: The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study

Financial news for SGEN dated on 2019-10-28: Stocks That Hit 52-Week Highs On Monday

Financial news for SGEN dated on 2019-10-27: The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings

Financial news for SGEN dated on 2019-10-23: Biotech Stock On The Radar: Immunomedics' Long Wait For Redemption

Financial news for SGEN dated on 2019-10-22: RBC Capital Maintains Outperform on Seattle Genetics, Raises Price Target to \$109

Financial news for SGEN dated on 2019-10-22: UPDATE: Deutsche Bank On Seattle Genetics Also Notes 'we maintain our HOLD rating as we believe the market appropriately values the company at current levels given the recent appreciation in shares and a general lack of near-term catalysts'

Financial news for SGEN dated on 2019-10-22: UPDATE: Deutsche Bank Maintains Hold On Seattle Genetics, Raises Target To \$95 As Firm Notes 'We increase the probability of success for tucatinib in HER2+ breast cancer in our SGEN model from 65% to 95%'

Financial news for SGEN dated on 2019-10-22: UPDATE: H.C. Wainwright Reiterates Buy On Seattle Genetics, Raises Target To \$140 As Firm Notes 'Remarkable HER2CLIMB topline positions Seattle Genetics as a strong player in breast cancer space'

Financial news for SGEN dated on 2019-10-22: Deutsche Bank Maintains Hold on Seattle Genetics, Raises Price Target to \$95

Financial news for SGEN dated on 2019-10-22: Oppenheimer Maintains Outperform on Seattle Genetics, Raises Price Target to \$110

Financial news for SGEN dated on 2019-10-22: The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug

Financial news for SGEN dated on 2019-10-22: H.C. Wainwright Reiterates Buy on Seattle Genetics, Raises Price Target to \$140

Financial news for SGEN dated on 2019-10-22: 38 Biggest Movers From Yesterday

Financial news for SGEN dated on 2019-10-21: Mid-Afternoon Market Update: Crude Oil

Down 1%; Innophos Holdings Shares Plummet

Financial news for SGEN dated on 2019-10-21: 33 Stocks Moving In Monday's Mid-Day Session

Financial news for SGEN dated on 2019-10-21: Mid-Day Market Update: Petmed Express Jumps On Upbeat Earnings; Infosys Shares Slide

Financial news for SGEN dated on 2019-10-21: Stocks That Hit 52-Week Highs On Monday

Financial news for SGEN dated on 2019-10-21: Mid-Morning Market Update: Markets Open Higher; Halliburton Sales Miss Estimates

Financial news for SGEN dated on 2019-10-21: Seattle Genetics Rallies To Record High On Positive Results From Midstage Breast Cancer Study

Financial news for SGEN dated on 2019-10-21: Seattle Genetics shares are trading higher following the release of positive data for the company's HER2CLIMB phase 2 trial.

Financial news for SGEN dated on 2019-10-21: 11 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for SGEN dated on 2019-10-21: 26 Stocks Moving in Monday's Pre-Market Session

Financial news for SGEN dated on 2019-10-18: Stocks That Hit 52-Week Highs On Friday

Financial news for SGEN dated on 2019-10-16: 4 Stocks Nearing Key Breakouts

Financial news for SGEN dated on 2019-10-10: Seattle Genetics Reports Initiation Of Phase 3 Trial Of Tucatinib In Combo With Dacyla For Patients with Advanced or Metastatic HER2-Positive Breast Cancer

Financial news for SGEN dated on 2019-10-08: Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks

Financial news for SGEN dated on 2019-10-08: UPDATE: Goldman On Puma Biotechnology Also Notes 'We believe that even if tucatinib is not differentiated on efficacy, it may garner more market share on greater tolerability based on mCRC data shown at ESMO'

Financial news for SGEN dated on 2019-10-01: A Look At Benzinga Pro's Most-Searched Tickers For October 1, 2019

Financial news for SGEN dated on 2019-10-01: 10 Biggest Price Target Changes For Tuesday

Financial news for SGEN dated on 2019-10-01: Oppenheimer Maintains Outperform on Seattle Genetics, Raises Price Target to \$92

Financial news for SGEN dated on 2019-10-01: The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines

Financial news for SGEN dated on 2019-10-01: 58 Biggest Movers From Yesterday

Financial news for SGEN dated on 2019-09-30: UPDATE: Piper Jaffray Maintains Overweight On Seattle Genetics, Raises Target To \$95 As Firm Notes 'Early EV-103 Data Points To Broad Utility In UBC'

Financial news for SGEN dated on 2019-09-30: Movers And Shakers At ESMO 2019: Immunomedics, G1 Therapeutics, Seattle Genetics And More

Financial news for SGEN dated on 2019-09-30: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for SGEN dated on 2019-09-30: Mid-Day Market Update: Thor Industries Surges On Earnings Beat; Benitec Biopharma Shares Slide

Financial news for SGEN dated on 2019-09-30: A Look At Benzinga Pro's Most-Searched Tickers For September 30, 2019

Financial news for SGEN dated on 2019-09-30: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Monday, September 30, 2019

Financial news for SGEN dated on 2019-09-30: Stocks That Hit 52-Week Highs On Monday

Financial news for SGEN dated on 2019-09-30: Mid-Morning Market Update: Markets Open

Higher; Cal-Maine Foods Misses Q1 Expectations

Financial news for SGEN dated on 2019-09-30: Seattle Genetics shares are trading higher after Piper Jaffray maintained an Overweight rating on the stock and raised the price target from \$75 to \$95. Seattle Genetics presented compelling initial data from the EV-103 study, which compared favorably to the current standard of care. Piper Jaffray also sees the potential for further upside from additional UBS opportunities.

Financial news for SGEN dated on 2019-09-30: 10 Biggest Price Target Changes For Monday

Financial news for SGEN dated on 2019-09-30: Piper Jaffray Maintains Overweight on Seattle Genetics, Raises Price Target to \$95

Financial news for SGEN dated on 2019-09-29: The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear

Financial news for SGEN dated on 2019-09-28: Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder Cancer at ESMO 2019

Financial news for SGEN dated on 2019-09-27: Seattle Genetics shares are trading higher after Goldman Sachs upgraded the company's stock to Buy.

Financial news for SGEN dated on 2019-09-26: Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.

Financial news for SGEN dated on 2019-09-24: Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.

Financial news for SGEN dated on 2019-09-22: The Week Ahead In Biotech: Spotlight On ESMO Conference

Financial news for SGEN dated on 2019-09-17: Seattle Genetics Highlights Presentations Of New Clinical Data From Multiple Studies Of Novel Targeted Therapies At ESMO Congress

Financial news for SGEN dated on 2019-09-16: Seattle Genetics, Astellas Report FDA Granted Priority Review For Enfortumab Vedotin Biologics License Application In Locally Advanced, Metastatic Urothelial Cancer

Financial news for SGEN dated on 2019-09-12: Oppenheimer Turns Bullish On Seattle Genetics, Says Optimism Fueled By Pipeline Readouts

Financial news for SGEN dated on 2019-09-12: UPDATE: Oppenheimer On Seattle Genetics Notes 'two upcoming near-term readouts could deliver value:'

Financial news for SGEN dated on 2019-09-12: UPDATE: Oppenheimer Upgrades Seattle Genetics To Outperform, Raises Target To \$82 Based On Firm's Review 'of two pipeline assets (Enfortumab Vedotin and tucatinib) that focus on less competitive later lines of treatment with strong data'

Financial news for SGEN dated on 2019-09-12: 10 Biggest Price Target Changes For Thursday

Financial news for SGEN dated on 2019-09-12: Oppenheimer Upgrades Seattle Genetics to Outperform, Raises Price Target to \$82

Financial news for SGEN dated on 2019-09-08: The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight

Financial news for SGEN dated on 2019-08-26: Benzinga's Top Upgrades, Downgrades For August 26, 2019

Financial news for SGEN dated on 2019-08-26: BTIG Initiates Coverage On Seattle Genetics with Neutral Rating

Financial news for SGEN dated on 2019-08-16: Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.

Financial news for SGEN dated on 2019-07-25: 50 Biggest Movers From Yesterday

Financial news for SGEN dated on 2019-07-24: 38 Stocks Moving In Wednesday's Mid-Day

Session

Financial news for SGEN dated on 2019-07-24: 24 Stocks Moving In Wednesday's Pre-Market Session

Financial news for SGEN dated on 2019-07-24: Seattle Genetics shares are trading lower after the company priced a 7.1 million share common stock offering at \$70 per share.

Financial news for SGEN dated on 2019-07-24: The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index

Financial news for SGEN dated on 2019-07-24: Seattle Genetics Prices 7.1M Share Public Offering of Common Stock @\$70/Share

Financial news for SGEN dated on 2019-07-23: Seattle Genetics shares are trading lower after the company reported a 6 million share common stock offering.

Financial news for SGEN dated on 2019-07-23: Seattle Genetics Reports 6M Share Common Stock Offering

Financial news for SGEN dated on 2019-07-23: Jim Cramer Weighs In On Berkshire Hathaway, Range Resources, Zynrba And More

Financial news for SGEN dated on 2019-07-18: 60 Biggest Movers From Yesterday

Financial news for SGEN dated on 2019-07-17: 44 Stocks Moving In Wednesday's Mid-Day Session

Financial news for SGEN dated on 2019-07-17: 10 Biggest Price Target Changes For Wednesday

Financial news for SGEN dated on 2019-07-17: Benzinga's Top Upgrades, Downgrades For July 17, 2019

Financial news for SGEN dated on 2019-07-17: Seattle genetics shares are trading higher after the company reported better-than-expected Q2 sales results. The company also raised its collaboration and license revenue guidance from \$95-\$110 million to \$110-\$125 million.

Financial news for SGEN dated on 2019-07-17: 30 Stocks Moving In Wednesday's Pre-Market Session

Financial news for SGEN dated on 2019-07-17: Piper Jaffray Upgrades Seattle Genetics to Overweight, Raises Price Target to \$75

Financial news for SGEN dated on 2019-07-16: Seattle genetics shares are trading higher after the company reported better-than-expected Q2 sales results, the company also raised its collaboration and license from \$95-\$110 million to \$110-\$125 million.

Financial news for SGEN dated on 2019-07-16: Seattle Genetics Sees ADCETRIS Net Product Sales \$610M-\$640M, Raises Collaboration And License Revenue Guidance From \$95M-\$110M To \$110M-\$125M

Financial news for SGEN dated on 2019-07-16: Seattle Genetics Q2 EPS \$(0.49) Misses \$(0.38) Estimate, Sales \$218.45M Beat \$189.81M Estimate

Financial news for SGEN dated on 2019-07-16: Astellas And Seattle Genetics Announce Submission Of Biologics License Application To FDA For Enfortumab Vedotin For Patients With Locally Advanced Or Metastatic Urothelial Cancer

Financial news for SGEN dated on 2019-07-16: Earnings Scheduled For July 16, 2019

Financial news for SGEN dated on 2019-07-13: The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings

Financial news for SGEN dated on 2019-07-11: Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.

Financial news for SGEN dated on 2019-07-10: Shares of several healthcare companies in the pharmaceutical space are trading lower after Amneal Pharmaceuticals announced a cost reduction plan in response to the continuing industry challenges. Amneal cut guidance as part of plan.

Financial news for SGEN dated on 2019-07-09: Seattle Genetics Option Alert: Jul 19 \$70 Calls at the Ask: 1690 @ \$2.15 vs 1575 OI; Ref=\$67.925

Financial news for SGEN dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for SGEN dated on 2019-06-17: Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.

Financial news for SGEN dated on 2019-06-14: Consider These New ETFs In A Megatrend Search

Financial news for SGEN dated on 2019-06-12: Seattle Genetics Announces Multiple ADCETRIS Presentations At Congress Of The European Hematology Association And The International Conference On Malignant Lymphoma Jun. 13-16

Financial news for SGEN dated on 2019-06-10: Seattle Genetics Highlights FDA Approval Of Genentech's Polivy, Which Utilizes The Company's Antibody-Drug Conjugate Technology

Financial news for SGEN dated on 2019-06-03: Shares of several biotechs are trading higher in sympathy with Amgen after the company presented the first clinical data evaluating a KRASG12C inhibitor, AMG 510, at ASCO 2019.

Financial news for SGEN dated on 2019-06-03: Seattle Genetics Reports Added Analyses Of ECHELON-1, ECHELON-2 Phase 3 Trials Of ADCETRIS At ASCO

Financial news for SGEN dated on 2019-06-03: Seattle Genetics Gives an Update on its Phase 2 Trial EV-201

Financial news for SGEN dated on 2019-06-01: The Week Ahead In Biotech: ASCO Presentations Pick Up The Pace

Financial news for SGEN dated on 2019-05-21: Seattle Genetics shares trading higher given overall strength in the biotech space. Not seeing company-specific news to justify the move higher.

Financial news for SGEN dated on 2019-05-16: Seattle Genetics shares are trading higher after the company highlighted presentations of new clinical data from multiple studies of novel targeted therapies at the ASCO annual meeting.

Financial news for SGEN dated on 2019-05-15: Seattle Genetics Highlights Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the American Society of Clinical Oncology

Financial news for SGEN dated on 2019-05-13: Shares of several healthcare companies are trading lower amid continued trade dispute between the US and China. Also, the United States filed a lawsuit against drug manufacturers alleging price fixing.

Financial news for SGEN dated on 2019-05-10: Shares of several healthcare companies are trading lower in sympathy with the overall market. The S&P 500 is trading lower 1%

Financial news for SGEN dated on 2019-05-03: Seattle Genetics Says Health Canada Approves ADCETRIS For The Treatment Of Previously Untreated Hodgkin Lymphoma

Financial news for SGEN dated on 2019-04-30: Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.

Financial news for SGEN dated on 2019-04-26: Seattle Genetics shares trading lower following below-consensus Q1 ADCETRIS sales of \$135 million and royalties of \$15.6 million.

Financial news for SGEN dated on 2019-04-26: The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug

Financial news for SGEN dated on 2019-04-25: Seattle Genetics Reaffirms FY19 ADCETRIS Sales \$610M-\$640M

Financial news for SGEN dated on 2019-04-25: Seattle Genetics Q1 EPS \$(0.08) Beats \$(0.29) Estimate, Sales \$195.199M Beat \$186.77M Estimate

Financial news for SGEN dated on 2019-04-25: The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings

Financial news for SGEN dated on 2019-04-21: The Week Ahead In Biotech: Conferences,

Clinical Trial Readouts, Earnings And IPOs

Financial news for SGEN dated on 2019-04-18: Shares of several healthcare companies are trading lower on continued weakness over concerns of 'Medicare for all' support within 2020 presidential candidates and the uncertainty over healthcare policy going into the election.

Financial news for SGEN dated on 2019-04-17: Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.

Financial news for SGEN dated on 2019-04-11: Seattle Genetics shares are trading lower after analysts at Stifel Nicolaus initiated coverage on the stock with a Hold rating and a \$70 price target.

Financial news for SGEN dated on 2019-04-11: Benzinga's Top Upgrades, Downgrades For April 11, 2019

Financial news for SGEN dated on 2019-04-11: Stifel Nicolaus Initiates Coverage On Seattle Genetics with Hold Rating, Announces \$70 Price Target

Financial news for SGEN dated on 2019-04-08: 54 Biggest Movers From Friday

Financial news for SGEN dated on 2019-04-05: 40 Stocks Moving In Friday's Mid-Day Session

Financial news for SGEN dated on 2019-04-05: Seattle Genetics shares are trading higher after RBC raised its price target from \$89 to \$90; noting that Merck pushing their estimated KEYNOTE-204 trial completion date from "any day now" to 2023 removes competitive overhang on Seattle's shares.

Financial news for SGEN dated on 2019-03-29: Seattle Genetics Reports Completion Of Enrollment In Phase 2 Trial Of Tisotumab Vedotin In Recurrent, Metastatic Cervical Cancer

Financial news for SGEN dated on 2019-03-28: Seattle Genetics shares are trading higher after the company reported positive topline data from its pivotal trial of Enfortumab for urothelial cancer.

Financial news for SGEN dated on 2019-03-28: Seattle Genetics, Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer

Financial news for SGEN dated on 2019-03-27: Benzinga's Top Upgrades, Downgrades For March 27, 2019

Financial news for SGEN dated on 2019-03-27: Berenberg Initiates Coverage On Seattle Genetics with Buy Rating, Announces \$95 Price Target

Financial news for SGEN dated on 2019-03-27: Seattle Genetics Highlights Antibody-Drug Conjugate Innovation And Immuno-Oncology Program At American Association For Cancer Research (AACR) Annual Meeting

Financial news for SGEN dated on 2019-03-26: Seattle Genetics Option Alert: Apr 18 \$80 Calls Sweep (33) near the Ask: 737 @ \$1.601 vs 483 OI; Earnings 4/25 After Close [est] Ref=\$74.71

Financial news for SGEN dated on 2019-02-15: The Daily Biotech Pulse: Acorda Swings To Profit, Achaogen Offering, Bioblast Strikes Sanfilippo Syndrome Deal

Financial news for SGEN dated on 2019-02-14: 13F From Ken Griffin's Citadel Advisors Shows New Stakes In Booking Holdings, Seattle Genetics, Macy's, Anaplan, Assurant, Cut Stakes In Morgan Stanley, Lowe's, Netflix, Visa, Lockheed Martin, Capital One, Microchip

Financial news for SGEN dated on 2019-02-11: Seattle Genetics Receives \$30M Milestone Payment From Takeda For European Commission Approval of ADCETRIS

Financial news for SGEN dated on 2019-02-11: 66 Biggest Movers From Friday

Financial news for SGEN dated on 2019-02-08: 48 Stocks Moving In Friday's Mid-Day Session

Financial news for SGEN dated on 2019-02-08: Seattle Genetics shares are trading lower after the company reported Q4 EPS of \$(0.75) missing the \$(0.43) estimate.

Financial news for SGEN dated on 2019-02-08: The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs

Financial news for SGEN dated on 2019-02-07: Seattle Genetics Sees FY19 ADCETRIS Net Product Sales \$610M-\$640M

Financial news for SGEN dated on 2019-02-07: Seattle Genetics Q4 GAAP EPS \$(0.75) May Not Compare \$(0.43) Estimate, Sales \$174.513M Beat \$163.71M Estimate

Financial news for SGEN dated on 2019-02-07: The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut

Financial news for SGEN dated on 2019-02-03: The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs

Financial news for SGEN dated on 2018-12-04: Seattle Genetics, Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas at ASH 2018

Financial news for SGEN dated on 2018-12-02: Seattle Genetics Announces Data from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS in Newly Diagnosed Advanced Hodgkin Lymphoma Presented at ASH 2018 Continue to Show Superior Clinical Activity of ADCETRIS in Combination with AVD vs ABVD

Financial news for SGEN dated on 2018-11-25: The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings

Financial news for SGEN dated on 2018-11-19: 55 Biggest Movers From Friday

Financial news for SGEN dated on 2018-11-16: 48 Stocks Moving In Friday's Mid-Day Session

Financial news for SGEN dated on 2018-11-16: Shares of Seattle Genetics are trading higher by 4.68% after the FDA approved Adcetris.

Financial news for SGEN dated on 2018-11-16: FDA Grants Approval Of Adcetris To Seattle Genetics

Financial news for SGEN dated on 2018-11-15: Seattle Genetics Reports FDA Has Granted Breakthrough Therapy Designation To ADCETRIS For Frontline Peripheral T-Cell Lymphomas; Designation Based On Positive Phase 3 ECHELON-2 Trial

Financial news for SGEN dated on 2018-11-15: Seattle Genetics Reports FDA Granted Breakthrough Therapy Designation For ADCETRIS For Frontline Peripheral T-Cell Lymphomas

Financial news for SGEN dated on 2018-11-14: Seattle Genetics Reports Initiation Of Phase 1 Trial Of SEA-BCMA For Patients With Relapse, Refractory Multiple Myeloma

Financial news for SGEN dated on 2018-11-05: Seattle Genetics Submits a Supplemental Biologics License Application for ADCETRIS to the FDA

Financial news for SGEN dated on 2018-11-01: Seattle Genetics Announces More Than 30 Presentations At ASH 2018 Highlighting Progress With Broad ADCETRIS Development Program On Dec 3

Financial news for SGEN dated on 2018-10-29: 71 Biggest Movers From Friday

Financial news for SGEN dated on 2018-10-26: 56 Stocks Moving In Friday's Mid-Day Session

Financial news for SGEN dated on 2018-10-26: Seattle Genetics shares are trading down 18.3% after the company missed Q3 EPS estimates.

Financial news for SGEN dated on 2018-10-26: The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default

Financial news for SGEN dated on 2018-10-26: Seattle Genetics Highlights Encore, Added Analyses From Phase 3 ECHELON-1 Trial For ADCETRIS In Combo With Chemotherapy In Frontline Advanced HL

Financial news for SGEN dated on 2018-10-25: Seattle Genetics, Inc. Q3 EPS \$(0.42) Misses \$(0.27) Estimate, Sales \$169.4M Beat \$166.92M Estimate

Financial news for SGEN dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for SGEN dated on 2018-10-21: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Financial news for SGEN dated on 2018-10-14: The Week Ahead In Biotech: ESMO

Conference, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for SGEN dated on 2018-10-05: 23 Stocks Moving In Friday's Pre-Market Session

Financial news for SGEN dated on 2018-10-04: Stocks Which Set New 52-Week High Yesterday, October 3rd

Financial news for SGEN dated on 2018-10-03: Stocks Which Set New 52-Week High Yesterday, October 2nd

Financial news for SGEN dated on 2018-10-03: 10 Biggest Price Target Changes For Wednesday

Financial news for SGEN dated on 2018-10-03: Barclays Maintains Overweight on Seattle Genetics, Raises Price Target to \$95

Financial news for SGEN dated on 2018-10-02: Stocks Which Set New 52-Week High Yesterday, October 1st

Financial news for SGEN dated on 2018-10-01: A Peek Into The Markets: US Stock Futures Up; Dow Futures Rise Over 200 Points

Financial news for SGEN dated on 2018-10-01: Seattle Genetics and Takeda Announces its Phase 3 ECHELON-2 Clinical Trial of ADCETRIS Met its Primary Endpoint

Financial news for SGEN dated on 2018-09-27: Stocks Which Set New 52-Week High Yesterday, September 26th

Financial news for SGEN dated on 2018-09-26: Stocks Which Set New 52-Week High Yesterday, September 25th

Financial news for SGEN dated on 2018-09-26: The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial

Financial news for SGEN dated on 2018-09-25: Leerink Swann Initiates Coverage On Seattle Genetics with Outperform Rating, Announces \$101 Price Target

Financial news for SGEN dated on 2018-09-24: Stocks Which Set New 52-Week High Friday, September 21

Financial news for SGEN dated on 2018-09-21: Seattle Genetics Announces ADCETRIS Approval in Japan for Frontline Hodgkin Lymphoma, Approval Triggers Milestone Payment to Seattle Genetics of \$10 Million

Financial news for SGEN dated on 2018-09-21: The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding

Financial news for SGEN dated on 2018-09-21: Stocks Which Set New 52-Week High Yesterday, September 20th

Financial news for SGEN dated on 2018-09-12: Stocks Which Set New 52-Week High Yesterday, September 11th

Financial news for SGEN dated on 2018-09-12: The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt

Financial news for SGEN dated on 2018-09-10: Stocks Which Set New 52-Week High Friday, September 7th

Financial news for SGEN dated on 2018-09-04: Stocks Which Set New 52-Week High Friday, August 31

Financial news for SGEN dated on 2018-08-31: Stocks Which Set New 52-Week High Yesterday, August 30th

Financial news for SGEN dated on 2018-08-31: The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage

Financial news for SGEN dated on 2018-08-30: Stocks Which Set New 52-Week High Yesterday, August 29th

Financial news for SGEN dated on 2018-08-24: Form 4 Filing Late Thursday Showed Seattle Genetics CEO Clay Siegall Sold 25K Shares at \$74.95

Financial news for SGEN dated on 2018-08-23: The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero

Financial news for SGEN dated on 2018-08-22: Stocks Which Set New 52-Week High Yesterday, August 21st

Financial news for SGEN dated on 2018-08-22: The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin

Financial news for SGEN dated on 2018-08-21: Stocks Which Set New 52-Week High Tues., Aug. 21, 2018

Financial news for SGEN dated on 2018-08-17: Stocks Which Set New 52-Week High Yesterday, August 16th

Financial news for SGEN dated on 2018-08-15: Stocks Which Set New 52-Week High Yesterday, August 14th

Financial news for SGEN dated on 2018-08-03: Form 4 Filing Late Thursday Showed Seattle Genetics Director Marc Lippman Sold 7.4K Shares At \$69.25

Financial news for SGEN dated on 2018-07-30: Stocks Which Set New 52-Week High Friday, July 27th

Financial news for SGEN dated on 2018-07-27: Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter

Financial news for SGEN dated on 2018-07-26: Seattle Genetics Sees Q3 Sales Of ADCETRIS To Be In Range Of \$130-\$135M

Financial news for SGEN dated on 2018-07-26: Seattle Genetics Q2 EPS \$0.47 Beats \$(0.39) Estimate, Sales \$170.173M Beat \$141.07M Estimate

Financial news for SGEN dated on 2018-07-26: Stocks Which Set New 52-Week High Yesterday, July 25th

Financial news for SGEN dated on 2018-07-26: Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold

Financial news for SGEN dated on 2018-07-26: Earnings Preview For Seattle Genetics

Financial news for SGEN dated on 2018-07-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for SGEN dated on 2018-07-17: UPDATE: RBC On Seattle Genetics Highlights Adcetris Trial Halt Was Strictly Administrative, Sees No Safety Concern

Financial news for SGEN dated on 2018-07-17: RBC Capital Comments On Seattle Genetics Midday, Says Is 'Not Concerned' By Report Of Halt Of NCI-Sponsored Trial Of Adcetris In HIV-Associated Hodgkin's Lymphoma

Financial news for SGEN dated on 2018-07-17: Seattle Genetics Shares Trading Lower As Traders Circulate Document That Shows Brentuximab Enrollment Was Halted, Issued Warning Letter

Financial news for SGEN dated on 2018-07-13: Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering

Financial news for SGEN dated on 2018-07-12: Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors, Trial to Inform Broader Development Program Strategy

Financial news for SGEN dated on 2018-07-12: Jim Cramer Shares His Thoughts On Cisco, Roku, Under Armour And More

Financial news for SGEN dated on 2018-07-11: tle Genetics Announces Publication Of Results From Two Tucatinib Phase 1b Clinical Trials In HER2-Positive Metastatic Breast Cancer

Financial news for SGEN dated on 2018-06-13: Seattle Genetics Reports Initial Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer

Financial news for SGEN dated on 2018-06-11: 10 Biggest Price Target Changes For Monday

Financial news for SGEN dated on 2018-06-11: Benzinga's Top Upgrades, Downgrades For June 11, 2018

Financial news for SGEN dated on 2018-06-11: SunTrust Robinson Humphrey Upgrades Seattle Genetics to Buy, Raises Price Target to \$80

Financial news for SGEN dated on 2018-06-05: Immunomedics Amended 13D Filing From Seattle Genetics Shows Reduced Stake From ~11.66M Shares To ~8.28M Shares, Or 4.9% Stake

Financial news for SGEN dated on 2018-06-04: UPDATE: Seattle Genetics Says Results From Patients Treated in North America Demonstrate 2-Year Modified Progression-Free Survival of 84.3% in the ADCETRIS Combination Arm Compared to 73.7% in the ABVD Arm

Financial news for SGEN dated on 2018-06-04: Seattle Genetics Reports Added Analyses From Phase 3 ECHELON-1 Trial Of ADCETRIS In Newly-Diagnosed Advanced Hodgkin Lymphoma At ASCO: Data Continues To Support Superior Clinical Activity Of ADCETRIS In Combo vs ABVD In Frontline Advanced Hodgkin Lymphoma

Financial news for SGEN dated on 2018-06-03: The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines

Financial news for SGEN dated on 2018-06-03: Seattle Genetics, Astellas Present on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy at #ASCO2018

Financial news for SGEN dated on 2018-05-03: 13D/A Filing Late Wednesday Showed Baker Bros Raised Stake In Seattle Genetics From ~45.723M shares to ~50.693M or 32.1%

Financial news for SGEN dated on 2018-04-27: Seattle Genetics Shares Up 7.6% After Co. Thursday Reported Mixed Q1 Results

Financial news for SGEN dated on 2018-04-26: Seattle Genetics Q1 EPS \$(0.73) Misses \$(0.42) Est., Sales \$140.6M Beats \$119.06M Est.

Financial news for SGEN dated on 2018-03-29: Biotech Stock Roundup: Protagonist Therapeutics, Verona, Amgen And More

Financial news for SGEN dated on 2018-03-26: Seattle Genetics, Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer

Financial news for SGEN dated on 2018-03-20: Seattle Genetics Announces FDA Approval of ADCETRIS In Combination With Chemo For Adults With Previously Untreated Stage III or IV Classical Hodgkin Lymphoma

Financial news for SGEN dated on 2018-03-07: Seattle Genetics Begins New Phase 1 Study in Relapsed or Refractory Multiple Myeloma

Financial news for SGEN dated on 2018-02-16: Seattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting Period With Respect To Proposed Acquisition Of Cascadian Therapeutics

Financial news for SGEN dated on 2018-02-14: JP Morgan Maintains Neutral on Seattle Genetics, Raises price target to \$66.00

Financial news for SGEN dated on 2018-02-14: JP Morgan Upgrades Seattle Genetics to Overweight

Financial news for SGEN dated on 2018-02-09: Seattle Genetics Reports Multi-Program Immuno-Oncology Collaboration Deal With Pieris Pharma

Financial news for SGEN dated on 2018-02-08: Seattle Genetics Commences Previously Announced Tender Offer for Cascadian Therapeutics at \$10/Share

Financial news for SGEN dated on 2018-02-06: Seattle Genetics Sees FY18 Sales \$470-\$505M vs \$575M Est.

Financial news for SGEN dated on 2018-02-06: Seattle Genetics Reports Q4 EPS \$(0.41) vs \$(0.43) Est., Sales \$129.6M vs \$116M Est.

Financial news for SGEN dated on 2018-01-31: Benzinga Pro's 6 Stocks To Watch Today

Financial news for SGEN dated on 2018-01-31: Seattle Genetics Announces a \$550M Offering Following the \$614M Acquisition of Cascadian Therapeutics

Financial news for SGEN dated on 2018-01-31: Cascadian Therapeutics to be Acquired by Seattle Genetics for \$10/Share Cash, Shares of Cascadian Closed at \$5.90/Share Tuesday

Financial news for SGEN dated on 2018-01-23: Seattle Genetics' Adcetris Gets EU Nod For Label Expansion

Financial news for SGEN dated on 2018-01-22: Seattle Genetics Announces ADCETRIS

Receives European Commission Approval for CD30-Positive Cutaneous T-Cell Lymphoma after at Least One Prior Systemic Therapy

Financial news for SGEN dated on 2018-01-08: JP Morgan Healthcare Conference Begins Today, Presenters Include: Gilead, Illumina, Seattle Genetics, Biogen, Incyte, Baxter, Regeneron, Walgreens, Alnylam, Edwards Lifesciences, Molina, Alexion, Celgene, Pfizer, Neurocrine Biosciences, and Jazz Pharma

Financial news for SGEN dated on 2018-01-02: FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS in Frontline Advanced Hodgkin Lymphoma

Financial news for SGEN dated on 2017-12-12: 42 Biggest Movers From Yesterday

Financial news for SGEN dated on 2017-12-11: 30 Stocks Moving In Monday's Mid-Day Session

Financial news for SGEN dated on 2017-12-10: Takeda, Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS in Frontline Advanced Hodgkin Lymphoma at #ASH2017

Financial news for SGEN dated on 2017-12-10: Seattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS in Frontline Mature T-Cell Lymphoma at #ASH2017

Financial news for SGEN dated on 2017-12-09: Seattle Genetics Says Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS in CD30-Expressing Cutaneous T-Cell Lymphoma at #ASH2017 Indicate Primary, Secondary Endpoints per Investigator Better than Previously Reported

Financial news for SGEN dated on 2017-12-07: Seattle Genetics Gives Updated Phase 1 Data for Ladiratuzumab Vedotin

Financial news for SGEN dated on 2017-11-09: Seattle Genetics Announces FDA Approval of ADCETRIS

Financial news for SGEN dated on 2017-11-08: Seattle Genetics, Astellas Pharma Reports Initiation Of Phase 1b Trial Of Enfortumaba Vedotin In Combo With Immune Checkpoint Inhibitor Therapies In Locally Advanced, Metastatic Urothelial Cancer: 'ADC Combination Study Focuses on First-Line Treatment'

Financial news for SGEN dated on 2017-11-02: Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS in Frontline Advanced Hodgkin Lymphoma

Financial news for SGEN dated on 2017-10-27: Bank of America Upgrades Seattle Genetics to Neutral

Financial news for SGEN dated on 2017-10-26: Seattle Genetics Raises FY17 Outlook: License Revenue From \$75M-\$90M to \$90M-\$100M, Royalty Sales From \$50M-\$55M to \$60M-\$65M

Financial news for SGEN dated on 2017-10-26: Seattle Genetics Reports EPS \$0.34 vs \$(0.23) In Same Qtr. Last Year, Sales \$135.3M vs \$112.81M Est.

Financial news for SGEN dated on 2017-10-20: The Market In 5 Minutes: Tax Overhaul In Focus As Senate Passes Budget Plan

Financial news for SGEN dated on 2017-10-20: Benzinga's Top Upgrades, Downgrades For October 20, 2017

Financial news for SGEN dated on 2017-10-20: Barclays Upgrades Seattle Genetics to Overweight

Financial news for SGEN dated on 2017-10-11: Seattle Genetics Announces 2 Clinical Collaborations to Evaluate SGN-LIV1A in Triple Negative Breast Cancer

Financial news for SGEN dated on 2017-10-11: Seattle Genetics Reports Additional Clinical Collaborations to Evaluate SGN-LIV1A in Triple Negative Breast Cancer

Financial news for SGEN dated on 2017-10-10: Seattle Genetics, Astellas Pharma Report Initiation Of Pivotal Trial Of Enfortumab Vedotin For Patients With Locally Advanced, Metastatic Urothelial Cancer

Financial news for SGEN dated on 2017-10-05: Jim Cramer Advises His Viewers On Teva, AT&T And More

Financial news for SGEN dated on 2017-10-03: UPDATE: Seattle Genetics Says 'In the 66% of Patients who Achieved Complete Remission, Both Median Overall Survival and

Progression-Free Survival Not Yet Reached'

Financial news for SGEN dated on 2017-10-03: Seattle Genetics, Takeda Highlight Publication 'Blood' Final Long-Term Survival Data From ADCETRIS Phase 2 Trial: 'Estimated 5-Year Overall Survival Rate 60%, 5-Year Progression-Free Survival Rate 39%'

Financial news for SGEN dated on 2017-10-02: 20 Biggest Mid-Day Gainers For Monday

Financial news for SGEN dated on 2017-10-02: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for SGEN dated on 2017-10-02: A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Manufacturing, Construction Spending Data

Financial news for SGEN dated on 2017-10-02: Seattle Genetics Reports Received FDA Breakthrough Therapy Designation For ADCETRIS In Frontline Advanced Hodgkin Lymphoma

Financial news for SGEN dated on 2017-09-19: Benzinga's Option Alert Recap From September 19

Financial news for SGEN dated on 2017-09-19: Seattle Genetics Option Alert: Oct 20 \$50 Puts Sweep (33) at the Bid: 578 @ \$1.005 vs 555 OI; Ref=\$52.534

Financial news for SGEN dated on 2017-09-15: RBC Initiated Coverage On 33 Pharma/Biotech Cos.

Financial news for SGEN dated on 2017-09-14: RBC Initiates Coverage on 6 Pharma Stocks After Hours

Financial news for SGEN dated on 2017-09-12: Morgan Stanley Healthcare Conference Continues Today, Presenters Include: Innoviva, Seattle Genetics, Lab Corp, Anthem, Juno Therapeutics, and Intercept Pharmaceuticals

Financial news for SGEN dated on 2017-09-08: European Society for Medical Oncology(ESMO) 2017 Congress Begins Today, Day 1 Of 5

Financial news for SGEN dated on 2017-08-29: Seattle Genetics Exercises its Option to Co-Develop Tisotumab Vedotin with Genmab

Financial news for SGEN dated on 2017-08-16: Seattle Genetics Reports FDA Accepted Supplemental BLA, Grants Priority Review For ADCETRIS In Cutaneous T-Cell Lymphoma

Financial news for SGEN dated on 2017-08-01: Seattle Genetics Buys Bothell Manufacturing Facility From Bristol-Myers Squibb

Financial news for SGEN dated on 2017-07-27: Seattle Genetics Reports Q2 EPS \$(0.39) vs \$(0.42) Est., Sales \$108.2M vs \$108.8M Est.

Financial news for SGEN dated on 2017-07-24: Seattle Genetics Reports Clinical Collaboration To Expand Therapeutic Evaluation Of SGN-LIV1A In Triple Negative Breast Cancer

Financial news for SGEN dated on 2017-06-26: 12 Biggest Mid-Day Losers For Monday

Financial news for SGEN dated on 2017-06-26: PiperJaffray Out On Seattle Genetics, Says ECHELON-1 Data Likely Good Enough To Warrant ADCETRIS Approval, Maintains Neutral Rating

Financial news for SGEN dated on 2017-06-26: Adam Feuerstein Tweets: \$SGEN - in ECHELON, Adcetris PFS improvement over standard of care is just under 5 percentage points. That's not spectacular.

Financial news for SGEN dated on 2017-06-26: Seattle Genetics Announces Phase 3 ECHELON-1 Trial Met its Primary Endpoint

Financial news for SGEN dated on 2017-06-20: Seattle Genetics Reports Submission Of BLA For ADCETRIS In Cutaneous T-Cell Lymphoma

Financial news for SGEN dated on 2017-06-19: 10 Biggest Mid-Day Losers For Monday

Financial news for SGEN dated on 2017-06-19: Mid-Morning Market Update: Markets Open Higher; EQT To Buy Rice Energy For \$6.7B

Financial news for SGEN dated on 2017-06-19: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for SGEN dated on 2017-06-19: Seattle Genetics Discontinues Phase 3 CASCADE Trial in Frontline Acute Myeloid Leukemia, Data Showed a Higher Rate of

Deaths

Financial news for SGEN dated on 2017-06-15: UPDATE: Seattle Genetics, Bristol-Myers Reports Combo Data Show 85% Objective Response Rate, 63% Complete Response Rate with an Acceptable Safety Profile

Financial news for SGEN dated on 2017-06-15: Seattle Genetics, Bristol-Myers Reports Interim Phase 1/2 Data Evaluating Combo Of ADCETRIS, Opdivo In Relapsed Hodgkin Lymphoma

Financial news for SGEN dated on 2017-06-15: Seattle Genetics and Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS and OPDIVO

Financial news for SGEN dated on 2017-06-07: Takeda and Seattle Genetics Reports Lancet Publication of Phase 3 ALCANZA Clinical Trial Data of ADCETRIS

Financial news for SGEN dated on 2017-06-02: Bristol-Myers Squibb and Seattle Genetics Expand Clinical Collaboration to Evaluate Combination of Opdivo and ADCETRIS in Phase 3 Trial

Financial news for SGEN dated on 2017-05-19: Companies Holding Shareholder Meetings Today Include: Mattel, Aetna, Yum! Brands, Seattle Genetics, Rosetta Stone, CBS, & Amgen

Financial news for SGEN dated on 2017-05-16: Bank Of America Health Care Conference Begins Today; Presenters Include Luminex, Acadia Healthcare, Express Scripts, Puma Biotech, Ultragenyx Pharma, Alexion, Medicines Co., Juno, TherapeuticsMD, & Seattle Genetics

Financial news for SGEN dated on 2017-05-05: Immunomedics Announces Mutual Deal with Seattle Genetics for Dissolving of Previously-Agreed Upon Exclusive Global Licensing Deal

Financial news for SGEN dated on 2017-05-05: Seattle Genetics Terminates License Agreement with Immunomedics for Sacituzumab Govitecan

Financial news for SGEN dated on 2017-04-27: Seattle Genetics Reports Q1 EPS \$(0.42) In-line With Est., Sales \$109.1M vs \$103.23M Est.

Financial news for SGEN dated on 2017-03-16: Oppenheimer Initiates Coverage On Seattle Genetics With Perform

Financial news for SGEN dated on 2017-03-15: Barclays Global Healthcare Conference Continues Today; Presenters Include HCA Holdings, Valeant, Incyte, Celgene, Cotiviti, Aetna, Anthem, Seattle Genetics, Teva Pharma, Pfizer, & Bristol-Myers

Financial news for SGEN dated on 2017-03-10: 8-K from Seattle Genetics Shows Delaware Court of Chancery Issued Temporary Restraining Order Enjoining Taking Any Action in Furthering of Closing of Deal between Co., Immunomedics Related to IMMU-132

Financial news for SGEN dated on 2017-03-08: Cowen Annual Healthcare Conference Concludes Today; Presenters Include Agilent Tech, Incyte, GW Pharma, Teva Pharma, NantKwest, Seattle Genetics, And Celgene

Financial news for SGEN dated on 2017-03-06: FDA Lifts Clinical Hold on Seattle Genetics' Phase 1 Trials of Vadastuximab Talirine

Financial news for SGEN dated on 2017-03-03: Immunomedics Says Co. Will Promptly Seek RRelief In Proceeding In Delaware Chancery Court While Co.. Continues To Take Steps To Protect Rights Of All Stockholders

Financial news for SGEN dated on 2017-02-27: Immunomedics Issues Letter Highlighting the Clear Decision to Vote for Immunomedics to Ensure Continued Value Creation

Financial news for SGEN dated on 2017-02-14: Immunomedics' Shareholder venBio Select Advisor Issues Statement In Opposition To Recent Partnership With Seattle Genetics, Files Motion For Injunction

Financial news for SGEN dated on 2017-02-10: Shkreli: I'd Short Immunomedics On The Bounce

Financial news for SGEN dated on 2017-02-10: Seattle Genetics Shares Higher Following Big Volume Spike

Financial news for SGEN dated on 2017-02-10: Mid-Day Market Update: Infinera Surges On Earnings Beat; ChannelAdvisor Shares Plunge

Financial news for SGEN dated on 2017-02-10: Bank of America Downgrades Seattle Genetics To Underperform

Financial news for SGEN dated on 2017-02-10: Immunomedics Enters Agreement With Seattle Genetics for Exclusive Rights to Commercialize Sacituzumab Govitecan, Immunomedic to Receive \$250M Upfront, Sell \$15M of Stock to Seattle Genetics

Financial news for SGEN dated on 2017-02-09: Seattle Genetics Sees FY17 Sales \$405M-\$445M

Financial news for SGEN dated on 2017-02-09: Seattle Genetics Reports Q4 EPS \$(0.39) vs \$(0.34) Est., Sales \$105.3M vs \$105M Est.

Financial news for SGEN dated on 2017-02-08: Seattle Genetics Shares Unaffected Premarket as FDA Site Shows Brentuximab Vedotin Designated for Orphan Drug Status

Financial news for SGEN dated on 2017-01-05: TheStreet's Adam Feuerstein Tweets '\$SGEN spox says Adcetris-Opdivo study halt is "purely procedural. Trial is going well. We are amending protocol to add additional patients.'

Financial news for SGEN dated on 2017-01-05: Seattle Genetics, Bristol-Myers Study of Opdivo and Adcetris Combo Halted Pending Protocol Amendment To Allow Additional Patients TO Be Enrolled and Treated To Further Characterize Safety And Efficacy

Financial news for SGEN dated on 2017-01-05: Seattle Genetics Shares Move to Session Lows as Hearing Enrollment Suspended for Adcetris, Opdivo Combo

Financial news for SGEN dated on 2017-01-05: Seattle Genetics Begins Phase 1 Trial of SGN-CD352A for Patients with Relapsed or Refractory Multiple Myeloma

Financial news for SGEN dated on 2016-12-30: 4 Big Biotech Losers Heading Into The New Year

Financial news for SGEN dated on 2016-12-28: 2 Reasons Seattle Genetics' Clinical Holds Were A Surprise

Financial news for SGEN dated on 2016-12-28: 5 Stocks You Should Be Watching Today

Financial news for SGEN dated on 2016-12-27: Mid-Afternoon Market Update: Ionis Pharma Rises After FDA Approval Of Spinraza; Seattle Genetics Shares Plummet

Financial news for SGEN dated on 2016-12-27: 10 Biggest Mid-Day Losers For Tuesday

Financial news for SGEN dated on 2016-12-27: Credit Suisse Says Seattle Genetics Surprise Clinical Hold Increases Risk To AML Programs, Decreases PT From \$70 To \$60

Financial news for SGEN dated on 2016-12-27: Mid-Day Market Update: Crude Oil Up Over 1%; Endologix Shares Slide

Financial news for SGEN dated on 2016-12-27: Seattle Genetics - No Bounce After Phase 1 Trial Put On Clinical Hold

Financial news for SGEN dated on 2016-12-27: Mid-Morning Market Update: Markets Open Higher; Groupe Casino Offers To Buy Cnova

Financial news for SGEN dated on 2016-12-27: Seattle Genetics Resumes Trade, Now Down 13.9%

Financial news for SGEN dated on 2016-12-27: Seattle Genetics To Resume At 8:30am ET

Financial news for SGEN dated on 2016-12-27: UPDATE: Holds On Vadastuximab Talirine To Evaluate Risk Of Hepatotoxicity In Patients With SGN-CD33A

Financial news for SGEN dated on 2016-12-27: Seattle Genetics Reports Clinical Hold on Several Phase 1 Trials of Vadastuximab Talirine

Financial news for SGEN dated on 2016-12-27: Seattle Genetics Halted News Pending

Financial news for SGEN dated on 2016-12-13: 10 Stocks With Lowest Close In Three Weeks

Financial news for SGEN dated on 2016-12-12: 8 Biggest Price Target Changes For Monday

Financial news for SGEN dated on 2016-12-12: Credit Suisse Downgrades Seattle Genetics to Neutral, Raises Target to \$70.00

Financial news for SGEN dated on 2016-12-09: Biotech Winners And Losers From ASH Conference

Financial news for SGEN dated on 2016-12-06: 8 Of The Biggest Biotech Announcements

Out Of The 2016 ASH Meeting

Financial news for SGEN dated on 2016-12-05: UPDATE: Seattle Genetics Says 'Phase 1 Trial of ADCETRIS in Combination with CHP Chemotherapy in Frontline Mature T-Cell Lymphoma Shows Four-Year Survival Rate of 80%'

Financial news for SGEN dated on 2016-12-05: Seattle Genetics Highlights Long-Term Follow-Up Data from ADCETRIS in T-Cell Lymphomas: Data Support Development Strategy to Establish ADCETRIS as Foundation of Care for CD30-Expressing Lymphomas

Financial news for SGEN dated on 2016-12-05: What Is The ASH Conference And Why Should Biotech Investors Care?

Financial news for SGEN dated on 2016-12-05: Seattle Genetics Highlights Phase 1 Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Says Data Supportive Of Phase 3 CASCADE Study

Financial news for SGEN dated on 2016-12-03: Takeda, Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS for CD30-Expressing Cutaneous T-Cell Lymphoma at ASH 2016

Financial news for SGEN dated on 2016-12-03: Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS in Frontline Diffuse Large B-cell Lymphoma at ASH 2016

Financial news for SGEN dated on 2016-11-29: Barclays Downgrades 5 Biopharma Stocks, Upgrades Pfizer And Alexion

Financial news for SGEN dated on 2016-11-29: Barclays Downgrades Seattle Genetics to Equal-Weight

Financial news for SGEN dated on 2016-11-10: Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS in Mycosis Fungoides and Primary Cutaneous Anaplastic Large Cell Lymphoma

Financial news for SGEN dated on 2016-11-09: Stocks Hitting 52-Week Highs

Financial news for SGEN dated on 2016-11-07: 10 Stocks That Rallied Four Days, Then Sold Off On Friday

Financial news for SGEN dated on 2016-11-03: 10 Stocks That Rallied Three Days On No News

Financial news for SGEN dated on 2016-10-27: Seattle Genetics Reports Q3 EPS \$(0.23) vs. Est. \$(0.29), Rev. \$106.3M vs. Est. \$101.7M

Financial news for SGEN dated on 2016-10-20: Seattle Genetics Shows Commitment to Improve Hodgkin Lymphoma Treatment Paradigm through Multiple ADCETRIS Data Presentations at ISHL 2016

Financial news for SGEN dated on 2016-10-17: 18 Stocks Moving In Monday's Pre-Market Session

Financial news for SGEN dated on 2016-10-13: 18 Stocks Moving In Thursday's Pre-Market Session

Financial news for SGEN dated on 2016-10-04: Seattle Genetics Names Dr. Vaughn Himes Chief Technical Officer

Financial news for SGEN dated on 2016-09-19: Seattle Genetics Initiates Phase 1 SGN Trial

Financial news for SGEN dated on 2016-09-19: Seattle Genetics Reports Initiation of Phase 1 Trial of SGN-CD123A for Patients with Relapses, Refractory Acute Myeloid Leukemia

Financial news for SGEN dated on 2016-09-15: 7 Biggest Price Target Changes For Thursday

Financial news for SGEN dated on 2016-09-15: Seattle Genetics No Longer On Goldman Sachs' Sell List

Financial news for SGEN dated on 2016-09-15: Benzinga's Top Upgrades

Financial news for SGEN dated on 2016-09-15: The Market In 5 Minutes: Apple Helps Lead Stocks Higher

Financial news for SGEN dated on 2016-09-15: Goldman Sachs Upgrades Seattle Genetics to Neutral, Raises PT to \$47.00, Removed From Americas Sell List

Financial news for SGEN dated on 2016-09-14: Stocks Hitting 52-Week Highs

Financial news for SGEN dated on 2016-09-09: Stocks Hitting 52-Week Highs

Financial news for SGEN dated on 2016-09-07: Here's Why Seattle Genetics' Adcetris Is A \$2 Billion Product

Financial news for SGEN dated on 2016-09-07: Benzinga's Top Initiations

Financial news for SGEN dated on 2016-09-07: Morgan Stanley Initiates Coverage on Seattle Genetics at Overweight, Announces \$60.00 PT

Financial news for SGEN dated on 2016-08-01: Takeda, Seattle Genetics Report Data from Phase 3 ALCANZA Trial of ADCETRIS for CD30-Expressing Cutaneous T-Cell Lymphoma: Met Primary Endpoint, Showed Highly Statistically Significant Improvement

Financial news for SGEN dated on 2016-07-27: Seattle Genetics Downgraded To Hold At Cantor Fitzgerald

Financial news for SGEN dated on 2016-07-26: Seattle Genetics Reports Q2 Loss -\$0.23 vs Est Loss Of -\$0.32, Rev \$95.4M vs \$94.14M Est

Financial news for SGEN dated on 2016-07-19: Incyte, Seattle Genetics Seen as Possible Acquisition Targets for their Cancer Treatments -Reuters

Financial news for SGEN dated on 2016-07-18: UPDATE: Seattle, Takeda Report 'Patients Who Achieved a Complete Remission Had Estimated Five-Year Overall Survival of 64%, Five-Year Progression-Free Survival of 52%'

Financial news for SGEN dated on 2016-07-18: UPDATE: Seattle Genetics, Takeda Report 'Estimated Five-Year Overall Survival Rate 41%, Five-Year Progression-Free Survival Rate 22%

Financial news for SGEN dated on 2016-07-18: Seattle Genetics, Takeda Pharma Report Publication of Final Data from ADCETRIS Phase 2 Trial

Financial news for SGEN dated on 2016-07-06: Seattle Genetics Reports EC Approves ADCETRIS for Treatment of Post-Transplant Hodgkin Lymphoma

Financial news for SGEN dated on 2016-06-11: Seattle Genetics Announces Vadastuximab Talirine Phase 1 Clinical Data Featured in Press Program and Oral Presentation Demonstrate 41% Complete Remission Rate, in Newly Diagnosed AML Patients Treated with 3A Combination Therapy

Financial news for SGEN dated on 2016-05-25: Seattle Genetics Initiates Phase 3 Trial For Vadastuximab Talirine For Acute Myeloid Leukemia

Financial news for SGEN dated on 2016-04-28: Seattle Genetics Reports Q1 EPS \$(0.15) vs. Est. \$(0.09), Rev. \$111.2M vs. Est. \$116M

Financial news for SGEN dated on 2016-04-18: Seattle Genetics Offers Data Supporting Antibody-Drug Conjugate, Novel Immuno-Oncology Programs at AACR Meeting

Financial news for SGEN dated on 2016-03-08: Baker Brothers Buys 502,523 Shares Of Seattle Genetics @\$32.45/Share -Form 4

Financial news for SGEN dated on 2016-03-07: The Most Notable Insider Buys And Sells Of Last Week

Financial news for SGEN dated on 2016-03-03: Benzinga's Top Initiations

Financial news for SGEN dated on 2016-03-02: SunTrust Robinson Humphrey Initiates Coverage on Seattle Genetics at Neutral, Announces \$34.00 PT

Financial news for SGEN dated on 2016-03-02: 3 Biotech Companies With Recent Large Insider Buying

Financial news for SGEN dated on 2016-03-01: Stocks To Watch During Cowen's 36th Annual Healthcare Conference

Financial news for SGEN dated on 2016-02-29: Zillow, Prospect Capital Lead List Of Notable Insider Transactions Last Week

Financial news for SGEN dated on 2016-02-26: 10 Stocks Moving In Friday's After-Hours Session

Financial news for SGEN dated on 2016-02-25: Seattle Genetics Starts Phase 1 Trial of SGN-CD19B for Patients with B-cell Non-Hodgkin Lymphoma

Financial news for SGEN dated on 2016-02-22: The 10 Most Notable Insider Transactions Last Week

Financial news for SGEN dated on 2016-02-22: Seattle Genetics Initiates Phase 1/2 Trial of Vadastuximab Talirine Combination Therapy for Patients with Untreated Myelodysplastic Syndrome (

Financial news for SGEN dated on 2016-02-10: Cantor Upgrades Seattle Genetics To Buy, Firm Says Guidance Is Conservative

Financial news for SGEN dated on 2016-02-10: Benzinga's Top Upgrades

Financial news for SGEN dated on 2016-02-10: Cantor Fitzgerald Upgrades Seattle Genetics to Buy

Financial news for SGEN dated on 2016-02-09: Seattle Genetics Sees FY16 Sales \$390M-\$430M vs \$414M Est.

Financial news for SGEN dated on 2016-02-09: Seattle Genetics Reports Q4 EPS \$(0.18) vs \$(0.20) Est., Sales \$93.5M vs \$88.3M Est.

Financial news for SGEN dated on 2016-02-04: Benzinga's Top Initiations

Financial news for SGEN dated on 2016-02-04: Barclays: Buy Seattle Genetics' Overlooked Pipeline, Stock Has 57% Upside

Financial news for SGEN dated on 2016-02-04: UPDATE: Seattle Genetics Says \$20M Milestone Payment Triggered by Annual ADCETRIS Net Sales Exceeding \$200M

Financial news for SGEN dated on 2016-02-04: Seattle Genetics Reports Commercial, Regulatory Progress Under ADCETRIS Collab with Takeda

Financial news for SGEN dated on 2016-02-04: Barclays Initiates Coverage on Seattle Genetics at Overweight, Announces \$51.00 PT

Financial news for SGEN dated on 2016-01-20: Credit Suisse Initiates Coverage on Seattle Genetics at Outperform, Announces \$52.00 PT

Financial news for SGEN dated on 2015-12-23: Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of ADCETRIS in Combination with Opdivo in Relapsed or Refractory Non-Hodgkin Lymphoma

Financial news for SGEN dated on 2015-12-07: Seattle Genetics Shows Commitment to Improve Hodgkin Lymphoma Treatment Paradigm Through Multiple ADCETRIS Data Presentations at ASH 2015

Financial news for SGEN dated on 2015-12-06: Seattle Genetics Highlights Data from SGN-CD19A Antibody-Drug Conjugate Program at #ASH2015

Financial news for SGEN dated on 2015-11-23: Seattle Genetics Initiates Phase 1/2 Clinical Trial of SGN-CD33A (Vadastuximab Talirine) Before or After Allogeneic Stem Cell Transplant in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Financial news for SGEN dated on 2015-11-18: Goldman Sees 2016 'Flight To Quality' In These Biotech Stocks

Financial news for SGEN dated on 2015-11-18: Goldman Sachs Initiates Coverage on Seattle Genetics at Sell, Announces \$33.00 PT

Financial news for SGEN dated on 2015-11-10: Director Baker Buys 934,624 Shares of Seattle Genetics @\$42.95/Share -Form 4

Financial news for SGEN dated on 2015-10-30: Benzinga's Top Upgrades

Financial news for SGEN dated on 2015-10-30: Piper Jaffray Upgrades Seattle Genetics to Neutral, Raises PT to \$44.00

Financial news for SGEN dated on 2015-10-29: Seattle Genetics Reports Q3 Loss of \$0.21/Share vs Loss of \$0.20/Share Est.

Financial news for SGEN dated on 2015-10-29: Seattle Genetics Reports Commencement of Phase 2 Trial of SGN-CD19A Combo Therapy in Relapsed, Refractory DLBCL

Financial news for SGEN dated on 2015-10-27: Seattle Genetics and Takeda Achieve Target Enrollment in Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS in Previously Untreated Advanced Hodgkin Lymphoma

Financial news for SGEN dated on 2015-10-19: Here's Why Biotechs Fell On Monday

Financial news for SGEN dated on 2015-10-19: Seattle Genetics Initiates Phase 2 Clinical Trial of ADCETRIS(r) (Brentuximab Vedotin) Combination Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Financial news for SGEN dated on 2015-10-07: Seattle Genetics Announces Initiation of Phase 1/2 Clinical Trial of ADCETRIS(r) (Brentuximab Vedotin) in Combination with Opdivo(r) (Nivolumab) in Second-line Hodgkin Lymphoma

Financial news for SGEN dated on 2015-09-23: American Eagle Outfitters, Sears And Others That Insiders Have Been Buying

Financial news for SGEN dated on 2015-09-16: The Baker Brothers Are Bullish On Seattle Genetics And DBV Technologies

Financial news for SGEN dated on 2015-09-15: Amended 13D Filing from Baker Bros. on Seattle Genetics Shows 25.9% Stake

Financial news for SGEN dated on 2015-09-14: Seattle Genetics Announces Exercise of Over-Allotment Option; Gross Proceeds for ~13.46M Share Offering at \$41/Share Totaled \$552M

Financial news for SGEN dated on 2015-09-10: Seattle Genetics Prices ~11.707M Share Offering of Common Stock @\$41.00/Share

Financial news for SGEN dated on 2015-09-09: Seattle Genetics Announces Proposed Public Offering of Common Stock, \$400M

Financial news for SGEN dated on 2015-09-09: Seattle Genetics Completes Enrollment in Phase 3 ALCANZA Clinical Trial Evaluating ADCETRIS in CD30-Expressing Cutaneous T-Cell Lymphoma (CTCL)

Financial news for SGEN dated on 2015-09-08: A Portfolio To Support Cancer Treatments In Time For Prostate Cancer Awareness Month

Financial news for SGEN dated on 2015-08-18: Sell Seattle Genetics' Latest Good News: Piper Jaffray

Financial news for SGEN dated on 2015-08-17: Seattle Genetics Announces FDA Regular Approval of ADCETRIS for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem Cell Transplantation Consolidation

Financial news for SGEN dated on 2015-07-30: Seattle Genetics Reports Q2 EPS \$(0.38) vs. Est. \$(0.26), Rev. \$77.096M vs. Est. \$77.97M

Financial news for SGEN dated on 2015-07-09: Seattle Genetics Begins Clinical Trial of ADCETRIS in Systemic Lupus Erythematosus, a Chronic Autoimmune Disease

Financial news for SGEN dated on 2015-06-17: Seattle Genetics Announces Multiple ADCETRIS(r) (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma

Financial news for SGEN dated on 2015-06-01: Seattle Genetics Announces Data Presentations at ASCO Related to ADCETRIS in AETHERA Post-Transplant Consolidation Setting

Financial news for SGEN dated on 2015-05-28: Seattle Genetics Announces Clinical Data Presentations from Multiple Antibody-Drug Conjugate Programs

Financial news for SGEN dated on 2015-05-23: Otonomy, Renren And Other Names To Watch Heading Into Next Week

Financial news for SGEN dated on 2015-05-20: Williams-Sonoma, Salesforce.com, Deckers Outdoor Lead Wednesday's After-Hours Movers

Financial news for SGEN dated on 2015-05-06: Credit Suisse Analysts Assume Coverage On 10 Biotech Stocks

Financial news for SGEN dated on 2015-05-05: Credit Suisse Assumes Seattle Genetics at Outperform, Announces \$51.00 PT

Financial news for SGEN dated on 2015-04-30: Seattle Genetics Reports Q1 GAAP Loss of \$0.17/Share vs Loss of \$0.19/Share Est., Sales \$82.2M vs \$74M Est.

Financial news for SGEN dated on 2015-04-20: Seattle Genetics Announces FDA Acceptance of sBLA, Granting of Priority Review for ADCETRIS in AETHERA Setting, Sets Aug. 18, '15 as PDUFA Date

Financial news for SGEN dated on 2015-04-13: Jefferies: 10 Buyout Targets To Own During The M&A Boom

Financial news for SGEN dated on 2015-03-16: Kinder Morgan, Seattle Genetics And Others Insiders Have Been Buying

Financial news for SGEN dated on 2015-03-01: American Express, General Electric And Other Stocks Insiders Have Been Buying

Financial news for SGEN dated on 2015-02-18: Seattle Genetics Submits Supplemental BLA To FDA For Phase 3 AETHERA Trial of ADCETRIS

Financial news for SGEN dated on 2015-02-17: Seattle Genetics Initiates Phase 1 Clinical Trial of SEA-CD40 for Multiple Types of Advanced Solid Tumors

Financial news for SGEN dated on 2015-02-17: Seattle Genetics Reports Advancement of Immuno-Oncology Program SEA-CD40 Into Phase 1 Trial for Advanced Solid Tumors

Financial news for SGEN dated on 2015-02-10: Seattle Genetics Reports Q4 EPS of \$(0.22) v \$(0.25) Est

Financial news for SGEN dated on 2015-02-10: Earnings Scheduled For February 10, 2015

Financial news for SGEN dated on 2015-02-08: From Coca-Cola To Tesla, Here Are The 68 Most Important Earnings Expectations For The Week

Financial news for SGEN dated on 2015-01-15: 10 Biotech Stories You Might've Missed This Week

Financial news for SGEN dated on 2015-01-12: Seattle Genetics Webcast Begins At JPMorgan Conference

Financial news for SGEN dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

Financial news for SGEN dated on 2015-01-12: Seattle Genetics and Bristol Myers Announces Collaboration on Two Drugs

Financial news for SGEN dated on 2015-01-02: New Biotech ETF From ALPS

Financial news for SGEN dated on 2014-12-18: Seattle Genetics Announces Initiation of Phase 1b Trial of SGN-CD33A in Combo with Frontline Standard of Care, as Consolidation Therapy for Acute Myeloid Leukemia

Financial news for SGEN dated on 2014-12-17: Amended 13D Filing from Baker Bros. Advisors on Seattle Genetics Shows Increased Stake from 20.27% as of Dec. 9th, 2014 to 22.6%

Financial news for SGEN dated on 2014-12-10: Seattle Genetics Director Baker Buys 1,247,896 Shares @\$33.82/Share -Form 4

Financial news for SGEN dated on 2014-12-08: Seattle Genetics Presents Phase 1 SGN-CD33A Data at ASH Annual Meeting

Financial news for SGEN dated on 2014-12-08: Seattle Genetics Presents Positive ADCETRIS Data in Diffuse Large B-cell Lymphoma at ASH Annual Meeting

Financial news for SGEN dated on 2014-12-08: Seattle Genetics Highlights Multiple ADCETRIS Data Presentations In Frontline & Salvage Hodgkin Lymphoma At ASH Annual Meeting

Financial news for SGEN dated on 2014-12-06: Seattle Genetics, Takeda Report Positive Phase 3 AETHERA Clinical Trial Data from ADCETRIS in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting

Financial news for SGEN dated on 2014-12-06: Seattle Genetics Presents Data from SGN-CD19A Antibody-Drug Conjugate at ASH Annual Meeting

Financial news for SGEN dated on 2014-11-04: 5 Health Care Stocks Hurting From The Affordable Care Act

Financial news for SGEN dated on 2014-10-31: Cantor Fitzgerald Upgrades Seattle Genetics, Inc. to Hold, Raises PT to \$35.00

Financial news for SGEN dated on 2014-10-30: Seattle Genetics, Inc. Reports Q3 EPS of \$(0.13) vs \$(0.24) Est; Revenue of \$75.90M vs \$66.92M Est

Financial news for SGEN dated on 2014-10-20: Bank Of America Q3 Small & Mid-Cap Biotech Preview

Financial news for SGEN dated on 2014-09-30: Benzinga's Top Downgrades

Financial news for SGEN dated on 2014-09-30: Bank of America Downgrades Seattle Genetics To Underperform

Financial news for SGEN dated on 2014-09-30: UPDATE: Bank Of America Downgrades Seattle Genetics, Inc. On Frontline Expectations

Financial news for SGEN dated on 2014-09-29: Seattle Genetics, Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS for Consolidation in Post-Transplant Hodgkin Lymphoma

Financial news for SGEN dated on 2014-09-26: UPDATE: Seattle Genetics Shares Rise 8% After-Hours, Following Announcement of Monday Conference Call on ADCETRIS Phase 3 AETHERA Data

Financial news for SGEN dated on 2014-09-26: Seattle Genetics to to Discuss Top-line Data from ADCETRIS Phase 3 AETHERA Clinical Trial on September 29, 2014

Financial news for SGEN dated on 2014-09-24: Seattle Genetics Offers Updated Progression-Free Survival, Overall Survival Data from ADCETRIS Frontline PTCL Phase 1 Trial

Financial news for SGEN dated on 2014-09-10: UPDATE: Genmab Will Make Upfront Fee of \$11M, Seattle Genetics Entitled to Get \$200M+ in Possible Milestones

Financial news for SGEN dated on 2014-09-10: Genmab, Seattle Genetics Enter Into Antibody-Drug Conjugate Deal

Financial news for SGEN dated on 2014-08-12: Seattle Genetics Initiates Phase 1 Clinical Trial Of SGN-CD70A

Financial news for SGEN dated on 2014-07-31: Seattle Genetics, Inc. Reports Q2 EPS of \$(0.14) vs \$(0.22) Est

Financial news for SGEN dated on 2014-07-09: UPDATE: UBS Upgrades Seattle Genetics

Financial news for SGEN dated on 2014-07-09: UBS Upgrades Seattle Genetics, Inc. to Buy, Maintains \$48.00 PT

Financial news for SGEN dated on 2014-06-17: Seattle Genetics Shares Fall 5%; May be Attributed to FDA Bulletin Date June 16: 'Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS) between January - March 2014'

Financial news for SGEN dated on 2014-06-08: Target And Others Insiders Have Been Buying

Financial news for SGEN dated on 2014-06-04: Seattle Genetics Shareholder Baker Brothers Life Sciences Buys 281,963 Shares @\$34.86/Share -Form 4

Financial news for SGEN dated on 2014-06-01: Seattle Genetics Presents Data from Phase 1 Clinical Trial of Antibody-Drug Conjugate SGN-CD19A in Non-Hodgkin Lymphoma at ASCO 2014

Financial news for SGEN dated on 2014-05-31: Seattle Genetics Presents Data from Multiple Collaborator Antibody-Drug Conjugate Programs at ASCO

Financial news for SGEN dated on 2014-05-14: Seattle Genetics To Present Antibody-Drug Conjugate At American Society of Clinical Oncology May 31-June 1

Financial news for SGEN dated on 2014-05-06: UPDATE: Bank Of America Upgrades Seattle Genetics

Financial news for SGEN dated on 2014-05-06: UPDATE: Bank of America Upgrades Seattle Genetics On Trial Risks

Financial news for SGEN dated on 2014-05-06: Benzinga's Top Upgrades

Financial news for SGEN dated on 2014-05-06: US Stock Futures Flat Ahead Of International Trade Data

Financial news for SGEN dated on 2014-05-06: Bank of America Upgrades Seattle Genetics, Inc. to Neutral, Lowers PO to \$40.00

Financial news for SGEN dated on 2014-05-01: Seattle Genetics, Inc. Reports Q1 EPS of \$(0.13) vs \$(0.21) Est; Revenue of \$68.30M vs \$64.62M Est

Financial news for SGEN dated on 2014-05-01: Form 8-K from Seattle Genetics Shows Co. Expecting Adcetris Phase 3 Athera Data in 2H

Financial news for SGEN dated on 2014-05-01: Seattle Genetics, Inc. Reports Q1 EPS of \$(0.13) vs \$(0.21) Est; Revenue of \$68.30M vs \$64.62M Est

Financial news for SGEN dated on 2014-04-11: Option Alert: Seattle Genetics Jun \$65 Call; 5,000 Contracts Traded vs 5,213 OI; Currently \$39.79

Financial news for SGEN dated on 2014-04-08: Seattle Genetics Achieves Milestones Under Collaboration with Takeda for Achieving First Commercial Sales of ADCETRIS

Financial news for SGEN dated on 2014-03-19: Seattle Genetics CEO Siegall: 'We are First and Foremost a Drug Company, But We Also Partner Our Technology with Other Companies'

Financial news for SGEN dated on 2014-03-19: Seattle Genetics CEO Siegall: 'ADCETRIS is Approved in 39 Countries'

Financial news for SGEN dated on 2014-03-19: Seattle Genetics CEO Siegall: 'We have a Lot of Different Trials'

Financial news for SGEN dated on 2014-03-19: Jim Cramer Interviews CEO Dr. Clay B. Siegall of Seattle Genetics on Mad Money

Financial news for SGEN dated on 2014-03-10: UPDATE: H.C. Wainwright & Co. Initiates Coverage on Seattle Genetics on Good Potential for Adcetris

Financial news for SGEN dated on 2014-03-10: HC Wainwright Initiates Coverage on Seattle Genetics, Inc. at Buy, Announces \$65.00 PT

Financial news for SGEN dated on 2014-02-25: Article in UK Daily Mail on Seattle Genetics' Adcetris (Brentuximab)

Financial news for SGEN dated on 2014-02-24: UPDATE: Bank of America Reinstates Coverage on Seattle Genetics as High Expectations are Priced In

Financial news for SGEN dated on 2014-02-24: Bank of America Reinstates Underperform on Seattle Genetics, Inc., Announces \$46.00 PO

Financial news for SGEN dated on 2014-02-12: Market Wrap For February 12: Markets Take a Breather, Senate Passes Debt Limit Bill

Financial news for SGEN dated on 2014-02-12: Needham Upgrades Seattle Genetics, Inc. to Buy

Financial news for SGEN dated on 2014-02-11: Seattle Genetics, Inc. Reports Q4 EPS of \$(0.13) vs \$(0.24) Est; Revenue of \$67.40M vs \$59.27M Est

Financial news for SGEN dated on 2014-02-05: Seattle Genetics Hits \$5M Sales Milestone Under ADCETRIS

Financial news for SGEN dated on 2014-01-17: UPDATE: Seattle Genetics Japanese Approval Triggers Milestone Payments of \$9M, Will Receive Two Milestone Payments from Takeda

Financial news for SGEN dated on 2014-01-17: Seattle Genetics Announces ADCETRIS Approval in Japan

Financial news for SGEN dated on 2014-01-13: Seattle Genetics Expecting Data from Phase 3 ADCETRIS Study Released During 2H'14

Financial news for SGEN dated on 2014-01-08: UPDATE: Seattle Genetics May Get Up to \$255M in License Fees

Financial news for SGEN dated on 2014-01-08: Seattle Genetics Expands Antibody-Drug Conjugate Pact with AbbVie, to Get \$25M Upfront

Financial news for SGEN dated on 2013-12-21: Office Depot, Seattle Genetics And Others Insiders Have Been Buying

Financial news for SGEN dated on 2013-12-09: Seattle, Genetics Takeda Highlight Long-term Follow-up Data from ADCETRIS Pivotal Clinical Trials at ASH

Financial news for SGEN dated on 2013-12-09: Seattle Genetics, International Speedway And Others Insiders Have Been Buying

Financial news for SGEN dated on 2013-12-07: Seattle Genetics Presents Interim Phase 1 from Novel Antibody-Drug Conjugate SGN-CD19A at ASH 2013

Financial news for SGEN dated on 2013-11-12: Gilead Sciences Leads In Rising Short Interest Among Biotechs

Financial news for SGEN dated on 2013-11-05: Seattle Genetics, Inc. Reports Q3 EPS of \$(0.19) vs \$(0.22) Est; Revenue of \$71.0M vs \$57.79M Est

Financial news for SGEN dated on 2013-10-25: Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, PCYC)

Financial news for SGEN dated on 2013-10-21: Seattle Genetics Initiates Phase 1 LIV-1-Positive Metastatic Breast Cancer Trial of SGN-LIV1A

Financial news for SGEN dated on 2013-10-11: Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

Financial news for SGEN dated on 2013-10-08: UBS Maintains Neutral on Seattle Genetics, Inc., Raises PT to \$48.00

Financial news for SGEN dated on 2013-10-02: Seattle Genetics Names Jonathan Drachman Chief Medical Officer

Financial news for SGEN dated on 2013-09-25: BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)

Financial news for SGEN dated on 2013-09-19: UODATE: Seattle Genetics FDA orphan Designation is for Adcetris for Treatment for Patients with Angioimmunoblastic T-cell Lymphoma

Financial news for SGEN dated on 2013-09-19: Seattle Genetics Gets FDA Orphan Designation for Adcetris to Treat Angioimmunoblastic T-Cell Lymphoma

Financial news for SGEN dated on 2013-09-14: Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, CELG, PCYC)

Financial news for SGEN dated on 2013-09-09: Seattle Genetics CEO Siegall: 'We Have 12 Partners and Do 1 to 2 Partnerships a Year'

Financial news for SGEN dated on 2013-09-09: Seattle Genetics CEO Siegall: 'T-Cell Lymphoma is Typically Trated with a 4-Drug Cocktail, Our Therapy is a 2-Drug Therapy and Double the Success Rate'

Financial news for SGEN dated on 2013-09-09: Seattle Genetics CEO Siegall: ''We Have Over 20 Clinical Trials'

Financial news for SGEN dated on 2013-09-09: Jim Cramer Interviews CEO Dr. Clay B. Siegall of Seattle Genetics on Mad Money

Financial news for SGEN dated on 2013-08-01: Jefferies Maintains Buy on Seattle Genetics, Inc., Raises PT to \$45.00

Financial news for SGEN dated on 2013-07-31: Seattle Genetics, Inc. Reports Q2 EPS of \$(0.06) vs \$(0.19) Est; Revenue of \$73.60M vs \$57.15M Est

Financial news for SGEN dated on 2013-07-02: Pfizer and Novartis Could Be Eyeing Onyx (PFE, NVS, ONXX)

Financial news for SGEN dated on 2013-07-01: Bernstein Believes Onyx Pharma Bid Would Need to be in \$140-150/Share Range to Sufficiently Entice Management

Financial news for SGEN dated on 2013-06-27: Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration

Financial news for SGEN dated on 2013-06-25: Recent Upside in Seattle Genetics Shares Being Attributed to Credit Suisse Defense, Says Concerns 'Overstated'

Financial news for SGEN dated on 2013-06-25: Hearing Merrill Spoke with Seattle Genetics Management, Says Pancreatitis Looks Like 1-Time Event, Not Caused by Adcetris

Financial news for SGEN dated on 2013-06-25: Seattle Genetics Halts Study of Lymphoma Drug Due to Safety Concerns -TheStreet

Financial news for SGEN dated on 2013-06-25: Seattle Genetics Enters Into New Antibody-Drug Conjugate Collaboration with Bayer

Financial news for SGEN dated on 2013-06-21: Hearing Seattle Genetics CEO Says Not Aware Of Pancreatitis Causing Any Adcetris Study To Be Halted; No Company-Run

Adcetris Trials Halted For Any Toxicity

Financial news for SGEN dated on 2013-06-21: Hearing JMP Confirms Investigator at Lugano Conference Said Seattle Genetics' Adcetris+Rituxan Study Might be Stopped Due to Pancreatitis

Financial news for SGEN dated on 2013-06-21: Seattle Genetics to Issue Clinical Data on ADCETRIS at ICML

Financial news for SGEN dated on 2013-06-19: Takeda, Seattle Genetics Report Data for Adcetris in Malignant Lymphoma Compared to Prior Therapy

Financial news for SGEN dated on 2013-06-10: UPDATE: Seattle Genetics Announces Initiation of Phase 1/2 Trial of ADCETRIS (Brentuximab Vedotin) in Combination with Bendamustine for Hodgkin Lymphoma Patients after Initial Relapse

Financial news for SGEN dated on 2013-06-10: Seattle Genetics Announces Commencement of Phase 1/2 Trial of ADCETRIS Combo with Bendamustine

Financial news for SGEN dated on 2013-06-02: Seattle Genetics Highlights ADCETRIS Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate Collaborator Data at ASCO

Financial news for SGEN dated on 2013-05-14: Seattle Genetics Announces ADCETRIS Supplemental BLA Accepted for Filing by the FDA

Financial news for SGEN dated on 2013-05-07: Seattle Genetics, Inc. Reports Q1 EPS of \$(0.14) vs \$(0.20) Est; Revenue of \$57.30M vs \$53.72M Est

Financial news for SGEN dated on 2013-05-07: Goldman Sachs Reinstates Neutral on Seattle Genetics, Inc., Announces \$37.00 PT

Financial news for SGEN dated on 2013-05-06: Three Top Performing Healthcare Stocks to Watch

Financial news for SGEN dated on 2013-03-26: Stocks Hitting 52-Week Highs

Financial news for SGEN dated on 2013-03-23: Moves in Smaller Health Care Stocks (ANAC, HALO, PBYY, QCOR)

Financial news for SGEN dated on 2013-03-22: Stocks Hitting 52-Week Highs

Financial news for SGEN dated on 2013-03-18: Seattle Genetics Submits Supplemental BLA to FDA for Retreatment, Extended Duration of Therapy with ADCETRIS

Financial news for SGEN dated on 2013-02-13: Needham Downgrades Seattle Genetics, Inc. to Hold, Removes \$25.00 Pt

Financial news for SGEN dated on 2013-02-12: Seattle Genetics, Inc. Reports Q4 EPS of \$(0.09) vs \$(0.11) Est; Revenue of \$63.90M vs \$57.21M Est

Financial news for SGEN dated on 2013-02-06: Seattle Genetics Commences Two Phase I Trials of SGN-CD19A

Financial news for SGEN dated on 2013-02-01: Seattle Genetics' ADCETRIS Approved by Health Canada for Treatment of Relapsed, Refractory HL, sALCL

Financial news for SGEN dated on 2013-01-25: Seattle Genetics Offers Data from ASG-5ME Phase I Trial

Financial news for SGEN dated on 2013-01-24: Seattle Genetics and Millennium Initiate Global Phase III Clinical Trial of ADCETRIS(r) (Brentuximab Vedotin) in Front-line CD30-Expressing Mature T-Cell Lymphoma (MTCL)

Financial news for SGEN dated on 2013-01-22: Seattle Genetics Spikes Higher

Financial news for SGEN dated on 2012-12-10: Seattle Genetics Offers Data on Next-Gen Antibody-Drug Conjugate SGN-CD33A at ASH Annual Meeting

Financial news for SGEN dated on 2012-12-09: Seattle Genetics Presents Encouraging ADCETRIS Data in CD30-Positive Non-Hodgkin Lymphomas and Other Malignancies

Financial news for SGEN dated on 2012-11-26: Seattle Genetics Confirms FDA Orphan Drug Status for ADCETRIS

Financial news for SGEN dated on 2012-11-20: Seattle Genetics Receives FDA Orphan Drug Status for Mycosis Fungoides - Bloomberg

Financial news for SGEN dated on 2012-11-13: UPDATE: Credit Suisse Initiates Seattle

Genetics at Outperform; Antibody Pure-Play

Financial news for SGEN dated on 2012-11-12: Credit Suisse Initiates Coverage on Seattle Genetics /wa at Outperform, Announces PT of \$28

Financial news for SGEN dated on 2012-11-08: UBS Maintains Seattle Genetics /wa at Neutral, Lowers PT from \$30 to \$27

Financial news for SGEN dated on 2012-11-08: Seattle Genetics Falls After Q3 Results and Analyst Downgrade

Financial news for SGEN dated on 2012-11-08: Oppenheimer Maintains Seattle Genetics /wa at Perform, Lowers PT from \$27 to \$23

Financial news for SGEN dated on 2012-11-07: Seattle Genetics /wa Reports Q3 EPS \$-0.12 vs \$-0.15 Est; Revenues \$49.8M vs \$52.66M Est

Financial news for SGEN dated on 2012-11-01: Millennium, Seattle Genetics Announce Phase 3 Clinical Trial of ADCETRIS

Financial news for SGEN dated on 2012-10-31: Seattle Genetics Announces EC Conditional Marketing Authorization ADCETRIS

Financial news for SGEN dated on 2012-10-23: Seattle Genetics Expands Antibody-Drug Pact with Abbott -Bloomberg

Financial news for SGEN dated on 2012-10-17: Seattle Genetics Announces Initiation of Phase II Trial of ADCETRIS

Financial news for SGEN dated on 2012-10-09: Seattle Genetics Will Get Undisclosed Milestone Payments

Financial news for SGEN dated on 2012-09-10: UBS Maintains Seattle Genetics /wa at Neutral, Raises PT from \$24 to \$30

Financial news for SGEN dated on 2012-08-24: Seattle Genetics Announces Initiation of a Phase Ib Trial of SGN-75

Financial news for SGEN dated on 2012-08-24: Seattle Genetics Announces Initiation of a Phase Ib Trial of SGN-75 in Combination with Everolimus for Patients with Renal Cell Carcinoma

Financial news for SGEN dated on 2012-08-20: Cantor Fitzgerald Initiates Coverage Seattle Genetics /wa at Hold, Announces PT of \$30

Financial news for SGEN dated on 2012-08-09: Oppenheimer Maintains Seattle Genetics /wa at Outperform, Raises PT from \$26 to \$28

Financial news for SGEN dated on 2012-08-09: UBS Maintains Seattle Genetics /wa at Neutral, Raises PT from \$23 to \$24

Financial news for SGEN dated on 2012-08-08: Seattle Genetics /wa Reports Q2 EPS \$-0.15 vs \$-0.15 Est; Revenues \$48.8M vs \$50.33M Est

Financial news for SGEN dated on 2012-08-08: Seattle Genetics /wa Reports Q2 EPS \$-0.15 vs \$-0.15 Est; Revenues \$48.8M vs \$50.33M Est

Financial news for SGEN dated on 2012-07-20: Seattle Genetics Announces ADCETRIS Receives Positive CHMP Opinion for Conditional Approval in European Union

Financial news for SGEN dated on 2012-07-20: Seattle Genetics Rises to 52-Week High on CHMP Positive Opinion on Adcertis

Financial news for SGEN dated on 2012-07-05: Benzinga's Top Initiations

Financial news for SGEN dated on 2012-07-05: ThinkEquity Initiates Seattle Genetics at Buy, Initiates PT to \$30

Financial news for SGEN dated on 2012-07-02: UPDATE: Piper Jaffray Downgrades Seattle Genetics to Underweight on Limited Sales Growth Outlook

Financial news for SGEN dated on 2012-07-02: Piper Jaffray Downgrades Seattle Genetics /wa from Neutral to Underweight, Lowers PT from \$22 to \$20

Financial news for SGEN dated on 2012-06-14: Seattle Genetics Highlights Updated Survival Data from ADCETRIS(r) Pivotal Trial in Patients with Relapsed or Refractory Hodgkin Lymphoma

Financial news for SGEN dated on 2012-06-13: Few trade ideas for tomorrow, June 14th

Financial news for SGEN dated on 2012-06-08: Seattle Genetics Trading 1.4% Higher on Heavy Volume; Currently at \$22.73

Financial news for SGEN dated on 2012-06-05: Seattle Genetics CEO Siegall: 'We Are Developing 7 Products that Target Different Types of Tumors'

Financial news for SGEN dated on 2012-06-05: Seattle Genetics CEO Siegall: 'This isn't Like Standard Chemotherapy; Patients Feel Much Better from Our Treatment'

Financial news for SGEN dated on 2012-06-05: Jim Cramer Interviews CEO Dr. Clay B. Siegall of Seattle Genetics on Mad Money

Financial news for SGEN dated on 2012-06-05: PREVIEW: Jim Cramer to Interview CEO of Seattle Genetics on Mad Money

Financial news for SGEN dated on 2012-06-04: Agensys and Seattle Genetics Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer

Financial news for SGEN dated on 2012-05-23: UPDATE: Seattle Genetics Announces Health Canada Accepts ADCETRIS(r) New Drug Submission for Review

Financial news for SGEN dated on 2012-05-23: Seattle Genetics Reports Health Canada Accepts Adcetris

Financial news for SGEN dated on 2012-05-10: Seattle Genetics Announces Data from Investigator Trial of ADCETRIS in Relapsed Cutaneous T-Cell Lymphoma; Data Demonstrate 75 Percent Response Rate in Patients with Relapsed CTCL

Financial news for SGEN dated on 2012-05-08: Seattle Genetics /wa Reports Q1 EPS \$-0.11 vs \$-0.12 Est; Revenues \$48.2M vs \$52.33M Est

Financial news for SGEN dated on 2012-04-30: Option Alert: Seattle Genetics May 22.5 Call; Block Trade: 1,543 Contracts; Currently \$19.97

Financial news for SGEN dated on 2012-03-21: Notable Call Options Activity in Seattle Genetics

Financial news for SGEN dated on 2012-02-13: Seattle Genetics Reports Q4 EPS \$(0.24) vs \$(0.31) Est; Revenues \$48.90M vs \$39.12M Est

Financial news for SGEN dated on 2012-02-13: Notable Put Options Activity in Seattle Genetics

Financial news for SGEN dated on 2012-01-30: Bank of America Optimistic Over Seattle Genetics' Adcetris

Financial news for SGEN dated on 2012-01-26: Benzinga's M&A Chatter for Thursday January 26, 2012

Financial news for SGEN dated on 2012-01-26: Seattle Genetics Announces Data from ADCETRIS in Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma

Financial news for SGEN dated on 2012-01-26: Seattle Genetics Spokesperson Would Not Comment on Earlier Merck Takeover Rumor

Financial news for SGEN dated on 2012-01-26: Positive Rumors Circulate About Seattle Genetics /wa

Financial news for SGEN dated on 2012-01-26: Seattle Genetics /wa Trading 4.1% Higher on Heavy Volume; Currently at \$19.08

Financial news for SGEN dated on 2012-01-13: Oppenheimer Reiterates Outperform, \$26 PT On Seattle Genetics

Financial news for SGEN dated on 2012-01-13: A Peek Into The Market Before The Trading Starts

Financial news for SGEN dated on 2012-01-13: Seattle Genetics Announces Updates to ADCETRIS Prescribing Information

Financial news for SGEN dated on 2012-01-05: JPMorgan Confab Kicks Off Biotech 2012

Financial news for SGEN dated on 2011-12-27: Best Biotech Stocks of 2011

Financial news for SGEN dated on 2011-12-15: Benzinga's M&A Chatter for Thursday December 15, 2011

Financial news for SGEN dated on 2011-12-13: Seattle Genetics Says Drug Well

Tolerated as Initial Treatment for Hodgkin's Lymphoma

Financial news for SGEN dated on 2011-12-12: Seattle Genetics and Millennium Highlight Pivotal Data on ADCETRIS in Relapsed or Refractory Systemic ALCL at ASH Annual Meeting

Financial news for SGEN dated on 2011-12-12: Seattle Genetics Reports Data From Multiple Presentations on ADCETRIS at ASH Annual Meeting

Financial news for SGEN dated on 2011-12-09: Five Biotech Stocks to Watch Going into Big Doctors' Meeting

Financial news for SGEN dated on 2011-12-09: Investor Ideas' Thursday's Biotech Stocks to Watch

Financial news for SGEN dated on 2011-12-09: Investor Ideas' Thursday's Biotech Stocks to Watch

Financial news for SGEN dated on 2011-12-07: Why Biotech Investors Must Understand the FDA's Adverse Events Reports

Financial news for SGEN dated on 2011-12-02: Jefferies Maintains Buy Rating and \$28 PT on Seattle Genetics

Financial news for SGEN dated on 2011-12-01: Seattle Genetics Down over 3.5%, May be Attributed to Analyst Call on Adverse Effects on Drug

Financial news for SGEN dated on 2011-11-04: Top Movers; MedAssets up 17%

Financial news for SGEN dated on 2011-11-04: UPDATE: JP Morgan Raises PT to \$16 on Seattle Genetics

Financial news for SGEN dated on 2011-11-04: UPDATE: Piper Jaffray Downgrades Seattle Genetics to Neutral

Financial news for SGEN dated on 2011-11-04: JP Morgan Raises PT on Seattle Genetics to \$16

Financial news for SGEN dated on 2011-11-03: Seattle Genetics Reports Q3 EPS \$(0.35) vs \$(0.46) Est; Revenues \$20.7M vs \$13.57M Est

Financial news for SGEN dated on 2011-10-31: Jefferies Maintains Buy Rating and \$25 PT on Seattle Genetics

Financial news for SGEN dated on 2011-10-25: Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS in CD30-Positive Non-Lymphoma Malignancies

Financial news for SGEN dated on 2011-10-18: Bank of America Raises PO On Seattle Genetics to \$22, Maintains Buy

Financial news for SGEN dated on 2011-10-13: UBS Changes PT on ADTN, VRUS, SGEN

Financial news for SGEN dated on 2011-10-12: Jefferies Maintains Buy Rating and \$25 PT on Seattle Genetics

Financial news for SGEN dated on 2011-10-03: Goldman Sachs Resumes Seattle Genetics at Neutral

Financial news for SGEN dated on 2011-10-03: Goldman Sachs Resumes Seattle Genetics at Neutral, \$20 PT

Financial news for SGEN dated on 2011-09-19: Midday Gainers; Pandora up Nearly 7%

Financial news for SGEN dated on 2011-09-13: Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer

Financial news for SGEN dated on 2011-09-12: Eight Stocks Insiders Are Buying

Financial news for SGEN dated on 2011-08-30: Pre-Market Movers

Financial news for SGEN dated on 2011-08-30: UPDATE: Bank Of America Raises Price Target On Seattle Genetics To \$19

Financial news for SGEN dated on 2011-08-30: Bank of America Raises PO On Seattle Genetics To \$19

Financial news for SGEN dated on 2011-08-29: Notable Put Options Activity in Seattle Genetics

Financial news for SGEN dated on 2011-08-23: UPDATE: Bank of America Lowers PT on Seattle Genetics from \$18 to \$17

Financial news for SGEN dated on 2011-08-23: Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS(tm) in CD30-Positive Non-Hodgkin Lymphoma

Financial news for SGEN dated on 2011-08-22: UPDATE: Siegall Claims Adcetris Targets Cancer Cells and Efficiently Kills Cancer Cells Alone; Says Drug is Unique in this Aspect and is First Drug for Hodgkin's Lymphoma in 30 Years

Financial news for SGEN dated on 2011-08-22: Seattle Genetics CEO Siegall Says Price of Adcentris is Priced in Right Way

Financial news for SGEN dated on 2011-08-22: UPDATE: Seattle Genetics New Drug Priced at \$13.5K/Dose; Siegall Defends its Price as a Function of Efficacy and Sustainability

Financial news for SGEN dated on 2011-08-22: Seattle Genetics CEO Clay Siegall Speaking on CNBC

Financial news for SGEN dated on 2011-08-22: Jefferies Comments on Seattle Genetics After Approval of Adcetris

Financial news for SGEN dated on 2011-08-22: Piper Jaffray Overweight On Seattle Genetics

Financial news for SGEN dated on 2011-08-19: UPDATE: Hearing Canaccord's George Farmer is Short in Seattle Genetics

Financial news for SGEN dated on 2011-08-19: Hearing Cannacord Says Sell Seattle Genetics into Strength

Financial news for SGEN dated on 2011-08-19: UPDATE: Seattle Genetics Announces FDA Accelerated Approval of ADCETRIS(tm) (Brentuximab Vedotin) for Two Indications

Financial news for SGEN dated on 2011-08-19: Seattle Genetics Receives FDA Approval on Lymphoma Drug

Financial news for SGEN dated on 2011-08-19: Seattle Genetics Spiking Higher on FDA Approval of Adcetris

Financial news for SGEN dated on 2011-08-08: UPDATE: Citadel Securities Initiates Coverage on Seattle Genetics

Financial news for SGEN dated on 2011-08-08: Citadel Initiates Seattle Genetics At Reduce, \$10 PT

Financial news for SGEN dated on 2011-07-21: UPDATE: William Blair Reiterates Outperform on Seattle Genetics

Financial news for SGEN dated on 2011-07-19: Canaccord Genuity Maintains Sell Rating on Seattle Genetics with \$10 PT

Financial news for SGEN dated on 2011-07-15: Seattle Genetics Down 9% on Heavy Volume

Financial news for SGEN dated on 2011-07-15: UPDATE: Jefferies Raises PT on Seattle Genetics to \$25

Financial news for SGEN dated on 2011-07-15: UPDATE: Oppenheimer Raising Its Price Target On Seattle Genetics (SGEN)

Financial news for SGEN dated on 2011-07-15: UPDATE: Seattle Genetics Confident FDA Pact Will be Agreed to Before Aug 30 PDUFA Date

Financial news for SGEN dated on 2011-07-15: Seattle Genetics Working on FDA Agreement for Confirmatory Studies

Financial news for SGEN dated on 2011-07-15: UPDATE: Oppenheimer Raises PT on Seattle Genetics to \$24

Financial news for SGEN dated on 2011-07-15: Seattle Genetics Trading Down Over 4.50% After FDA Announced It Would Speed Up Approval of the Company's Cancer Drug

Financial news for SGEN dated on 2011-07-15: Jefferies Raises PT On Seattle Genetics To \$25

Financial news for SGEN dated on 2011-07-15: Oppenheimer Raises PT On Seattle Genetics To \$24

Financial news for SGEN dated on 2011-07-14: PREVIEW: Seattle Genetics to Resume Trading at 5:05 p.m.

Financial news for SGEN dated on 2011-07-14: Seattle Genetics Announces Unanimous Recommendations from FDA Advisory Committee

Financial news for SGEN dated on 2011-07-14: Update On Seattle Genetics FDA Meeting

Financial news for SGEN dated on 2011-07-14: Biggest Gainers Pre-Market Going Into the Opening Bell

Financial news for SGEN dated on 2011-07-14: Last Nights Noteables July 14th

Financial news for SGEN dated on 2011-07-14: A Peek Into The Market Before The Trading Starts

Financial news for SGEN dated on 2011-07-14: UPDATE: Seattle Genetics Common Stock Halted; FDA to Discuss Company's Application for ADCETRIS

Financial news for SGEN dated on 2011-07-14: Seattle Genetics Halted, Pending News

Financial news for SGEN dated on 2011-07-13: Summer Swing 07-13-2011

Financial news for SGEN dated on 2011-07-13: Dollar down, Market up 07-13-2011

Financial news for SGEN dated on 2011-07-13: Puts Purchased on Seattle Genetics

Financial news for SGEN dated on 2011-07-12: Bank of America Merrill Lynch Discusses Seattle Genetics After FDA Briefing

Financial news for SGEN dated on 2011-07-12: Jefferies Says Buy Seattle Genetics

Financial news for SGEN dated on 2011-07-08: Options Brief: Seattle Genetics

Financial news for SGEN dated on 2011-07-06: Piper Jaffray Reiterates OW Rating on Seattle Genetics

Financial news for SGEN dated on 2011-06-29: Stocks to Watch for 6/29/11: Fresh 52 Week Highs and Lows

Financial news for SGEN dated on 2011-06-27: Seattle Genetics Achieves \$5M Milestone Under Millennium Collaboration for European Medicines Agency Acceptance of Brentuximab Vedotin MAA

Financial news for SGEN dated on 2011-06-22: Mad Money Lightning Round OT: Cramer Is A Buyer Of SGEN, IBM, ANR

Financial news for SGEN dated on 2011-06-21: Stocks to Watch for 6/21/11: Fresh 52 Week Highs and Lows

Financial news for SGEN dated on 2011-06-17: Seattle Genetics Announces Promotion of Eric Dobmeier to COO

Financial news for SGEN dated on 2011-06-16: Seattle Genetics Announces FDA Advisory Committee to Review Brentuximab Vedotin for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL

Financial news for SGEN dated on 2011-06-13: Piper Jaffray Reiterates Overweight Rating On Seattle Genetics

Financial news for SGEN dated on 2011-06-07: Jefferies Maintains Buy on Seattle Genetics

Financial news for SGEN dated on 2011-06-06: Seattle Genetics Presents SGN-75 Clinical Data Suggesting It Is Well Tolerated

Financial news for SGEN dated on 2011-06-06: Bank Of America Comments On Seattle Genetics Regulatory Discussions

Financial news for SGEN dated on 2011-06-06: Jefferies Provides Color on Seattle Genetics

Financial news for SGEN dated on 2011-05-25: Options Brief: Seattle Genetics, Inc.

Financial news for SGEN dated on 2011-05-02: J.P. Morgan Maintains Neutral Rating On SGEN

Financial news for SGEN dated on 2011-05-02: UPDATE: Seattle Genetics Trading Higher Pre-Market After FDA News (SGEN)

Financial news for SGEN dated on 2011-05-02: Seattle Genetics Announces FDA Accepts Brentuximab Vedotin BLAs for Filing and Grants Review for Hodgkin Lymphoma and Systemic ALCL (SGEN)

Financial news for SGEN dated on 2011-04-25: Hoo-ah! Five Stocks to Consider on Al Pacino's Birthday

Financial news for SGEN dated on 2011-04-13: Seattle Genetics Announces Tenth Collaborator ADC Program in Clinical Development

Financial news for SGEN dated on 2011-04-12: Brean Murray Carret Reiterates Sell Rating On Seattle Genetics

Financial news for SGEN dated on 2011-04-06: Seattle Genetics Reports Brentuximab Vedotin Data at EBMT Annual Meeting

Financial news for SGEN dated on 2011-04-06: Seattle Genetics Reports All Patients Relapsed After Lymphoma Trial Transplant (SGEN)

Financial news for SGEN dated on 2011-04-05: Seattle Genetics Highlights ADC Technology Research at AACR

Financial news for SGEN dated on 2011-03-25: Mad Money Lightning Round: Cramer Likes CB Richard Ellis (SGEN, CBG, BIDU, SINA, ACW, CNH, POT)

Financial news for SGEN dated on 2011-03-22: Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Abbott

Financial news for SGEN dated on 2011-03-01: Seattle Genetics and Millennium Announce Initiation of a Phase I Clinical Trial of Brentuximab Vedotin in Combination with Chemotherapy

Financial news for SGEN dated on 2011-02-17: Jefferies Initiates Seattle Genetics at Buy (SGEN)

Financial news for SGEN dated on 2011-02-17: Jefferies Raises PT On Seattle Genetics To \$22

Financial news for SGEN dated on 2011-02-09: Piper Jaffray Comments On Seattle Genetics Following Earnings Report

Financial news for SGEN dated on 2011-02-09: Oppenheimer Has Outperform On Seattle Genetics (SGEN)

Financial news for SGEN dated on 2011-02-09: Oppenheimer Raises PT On Seattle Genetics To \$17

Financial news for SGEN dated on 2011-02-02: Seattle Genetics Prices 10M Share Offering at \$15.50

Financial news for SGEN dated on 2011-02-01: Seattle Genetics Announces Proposed Public Offering

Financial news for SGEN dated on 2011-01-27: Calls Purchased on Seattle Genetics, Inc. (SGEN)

Financial news for SGEN dated on 2011-01-19: Piper Jaffray Reiterates Overweight Rating on Seattle Genetics (SGEN)

Financial news for SGEN dated on 2011-01-11: Seattle Genetics Rises On CEO's Appearance On CNBC (SGEN)

Financial news for SGEN dated on 2011-01-11: J.P. Morgan Healthcare Confab: Live Blog

Financial news for SGEN dated on 2011-01-07: Biotech Stock Mailbag: Best Stocks to Watch in '11

Financial news for SGEN dated on 2011-01-06: Seattle Genetics Announces Collaboration with Pfizer

Financial news for SGEN dated on 2011-01-05: Piper Jaffray's Favorite Antibody Plays (SGEN, MITI, REGN)

Financial news for SGEN dated on 2010-12-15: 15 Biotech Stock Predictions for 2011

Financial news for SGEN dated on 2010-12-11: Biotech Sector Weekly Rewind

Financial news for SGEN dated on 2010-12-06: J.P. Morgan Reiterates Neutral Rating on

Seattle Genetics (SGEN)

Financial news for SGEN dated on 2010-11-08: Seattle Genetics and Millennium to Present Brentuximab Vedotin Clinical Data

Financial news for SGEN dated on 2010-11-02: JP Morgan Downgrades SGEN To Neutral

Financial news for SGEN dated on 2010-11-01: Seattle Genetics Reports Third Quarter EPS of \$(0.34)

Financial news for SGEN dated on 2010-10-12: Price Target Changes On SGEN, FFIV, EBAY

Financial news for SGEN dated on 2010-10-04: NASDAQ Stocks Hitting 52-Week Highs (ACTL, SGEN, SIRI, DDMX)

Financial news for SGEN dated on 2010-09-29: Benzinga's Top Pre-Market NASDAQ Gainers (SGEN, CADC, GERN, CRUS)

Financial news for SGEN dated on 2010-09-28: Benzinga's Top Upgrades (PHM, LVS, SGEN, APSG)

Financial news for SGEN dated on 2010-09-27: SGEN Announces Favorable SGN-35 Results; Shares Up

Financial news for SGEN dated on 2010-09-27: Biotech Stocks Trading High Volume (UVFT.OB, KBLB.OB, SGEN, GENZ)

Financial news for SGEN dated on 2010-09-27: Benzinga's Volume Movers (SGEN, HMIN, BIDU, ATPG)

Financial news for SGEN dated on 2010-09-27: Benzinga's Top Pre-Market NASDAQ Gainers (SGEN, JBLU, GFRE, ATPG)

Financial news for SGEN dated on 2010-09-27: Biotechnology Stock News; Seattle Genetics (Nasdaq: SGEN) and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Pivotal Trial in Relapsed and Refractory Hodgkin Lym

Financial news for SGEN dated on 2010-09-27: Biotechnology Stock News; Seattle Genetics (Nasdaq: SGEN) and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Pivotal Trial in Relapsed and Refractory Hodgkin Lym

Financial news for SGEN dated on 2010-09-14: Genmab and Seattle Genetics Enter into Research Collaboration (SGEN)

Financial news for SGEN dated on 2010-09-13: Benzinga's Top Pre-Market NASDAQ Losers (SGEN, ARNA, HGSI, GOLD)

Financial news for SGEN dated on 2010-07-27: Seattle Genetics Reports Second Quarter Financial Results

Financial news for SGEN dated on 2010-07-01: Calls Purchased on Seattle Genetics (SGEN)

Financial news for SGEN dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for SGEN dated on 2010-03-03: Benzinga's News Roundup (BJ, JOYG, NFLX, SGEN)

Financial news for SGEN dated on 2010-02-10: Seattle Genetics, Inc.'s (SGEN) Fourth-Quarter Review

Financial news for SGEN dated on 2009-12-21: Benzinga's Top Pre- Market Gainers (CHTT, BUCY, SGEN, INCY, MAIL, ATHX)

Financial news for SGEN dated on 2009-12-15: NASDAQ's Most Advanced Today (LIMS, ARRY, SGEN, JASO, JAZZ)

Financial news for SGEN dated on 2009-12-15: Benzinga's Top Pre- Market Gainers (LIMS, SGEN, CLNE, ARRY, JASO, JAZZ, SPWRA)

Financial news for SGEN dated on 2009-11-30: SGEN to Post Mixed Results in 2010

Financial news for SGEN dated on 2009-10-05: Biggest Losers (CVM, SGEN, SCLN, FOLD, FTBK)

Financial news for SGEN dated on 2009-08-16: Two Life Science Companies Manage to Pry Open IPO Window